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ABSTRACT: Deregulation of the transcriptional repressor BCL6
enables tumorigenesis of germinal center B-cells, and hence BCL6
has been proposed as a therapeutic target for the treatment of
diffuse large B-cell lymphoma (DLBCL). Herein we report the
discovery of a series of benzimidazolone inhibitors of the protein−
protein interaction between BCL6 and its co-repressors. A subset
of these inhibitors were found to cause rapid degradation of BCL6,




which reduces BCL6 levels in a lymphoma xenograft mouse model
following oral dosing.
■ INTRODUCTION
BCL6 (B-cell lymphoma 6 protein) is a transcriptional
repressor that plays a key role in the formation and
maintenance of germinal centers during the process of
antibody affinity maturation.1−3 By binding to DNA via its
zinc fingers and recruiting one of its co-repressors (NCoR,
SMRT, or BCOR) to its dimeric BTB domain, BCL6 represses
genes involved in cell cycle control, cell death, differentiation,
and the DNA damage response. This action enables B-cells in
the germinal center to proliferate rapidly, evade growth
checkpoint controls, and tolerate high levels of DNA damage.
These features are required for the process of somatic
hypermutation of antibodies but are also among the hallmarks
of cancer;4,5 hence deregulation of BCL6 can lead to
lymphomagenesis. Most B-cell lymphomas arise from germinal
center B-cells, which are dependent on continued expression of
BCL6 for survival.1 Recruitment of co-repressors is essential
for the repressive and oncogenic functions of BCL6, and
disruption of this interaction is sufficient to inhibit lymphoma
cell growth.6,7 We sought to discover compounds that disrupt
the protein−protein interaction (PPI) between the BTB
domain of BCL6 and its co-repressors to alleviate BCL6-
mediated gene repression, inhibit lymphoma cell growth, and
identify new treatments for BCL6-driven lymphomas. Follow-
ing on from earlier publications that identified small molecule
or peptidomimetic compounds with moderate potency against
BCL6,8−10 the recent publication of high-potency small
molecules has established the ligandability of the BCL6 BTB
domain dimer.11−13 Proteolysis targeting chimeras (PRO-
TAC)14 and non-PROTAC degrader compounds that trigger
the proteosomal degradation of BCL615 have also been
reported. However, to date, no compound has been reported
to be suitable for use as an in vivo probe to investigate the
effect of degradation of BCL6. In this study we report the
discovery not only of compounds that can potently inhibit
BCL6 function by disrupting the PPI with its co-repressors but
also of a subset of molecules that trigger the rapid degradation
of BCL6. Further optimization of this series led to compound
1 (CCT369260), which shows degradation of tumoral BCL6
in vivo following oral dosing in a lymphoma xenograft mouse
model.
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■ RESULTS
Chemistry: Synthesis of Compounds. Initial hit
compounds 2 and 3 and follow-up compound 4 were obtained
from commercial vendors, while the cyclopropyl compound 5
and benzimidazolone 6 (CCT365386) were prepared by single
step nucleophilic aromatic substitution (SNAr) reaction from
available building blocks. Compounds with alkyl substituents
in the benzimidazolone-N3 position could be synthesized by
stepwise alkylation of nitro-compound 7, reduction, and SNAr
reaction, as exemplified in the preparation of 11a (Scheme 1).
In order to facilitate the optimization of this position (as
shown in Table 2), we developed conditions to allow the
Scheme 1. Final Step Diversification of Benzimidazolone N3 Positiona
aReagents and conditions: (a) 2-ethyloxirane, cesium carbonate, DMF, 120 °C, 1 h; (b) sodium dithionite, ethanol/DMSO, rt to 90 °C; (c) 2,4-
dichloropyridine-3-carbonitrile, DIPEA, DMA, 120 °C, 30−45 min; (d) (2R)- or (2S)-ethyloxirane, cesium carbonate, DMF, 120 °C, 1 h, then 140
°C, 1 h; (e) alkyl bromide or tosylate, cesium carbonate, DMF, 60 °C, 3 days or 120−140 °C, 1 h.
Scheme 2. Synthesis of Key Intermediate 16a
aReagents and conditions: (a) disuccinimidylcarbonate, MeCN, rt, 18 h, up to 11g scale, 86−99% yield; (b) cesium carbonate, MeCN, reflux, 4 h,
12 g scale, 92% yield; (c) TsCl, NEt3, DCM, 0 °C to rt, up to 40g scale, 60−72% yield; (d) 10% Pd/C, 1 atm H2, ethanol, 60 °C, 3 h, 6 g scale,
quant.
Scheme 3. Synthesis of Compounds from Table 3, Investigating Different Substitution Patterns on Pyrimidine or Pyridine
Ringsa
aReagents and conditions: (a) heteroaryl chloride, DIPEA, NMP or DMF, 80−120 °C, 30 min; (b) 4-bromo- or iodopyridine, Xantphos,
Pd2(dba)3, cesium carbonate, NMP/toluene, 140 °C, 1 h.
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addition of this group as the final step (Scheme 1, steps d and
e), using intermediate 9. The use of alkyl halides or epoxides as
electrophiles under these conditions gave primarily the desired
regioisomer, although in most cases minor products corre-
sponding to alkylation at the 4-pyridylamine were also
observed in the reaction mixture and required HPLC
purification to separate.
In order to vary the substituent of the 5-amino group on the
benzimidazolone (labeled as R4 in Table 3), it was necessary
first to scale up the synthesis of the 1,3-disubstituted 5-
aminobenzimidazol-2-one. Cyclization of commercially avail-
able nitrodianiline 12 using disuccinimidylcarbonate pro-
ceeded in high yield and was followed by alkylation with
tosylate 14a, then hydrogenation to reduce the nitro group and
form aniline 16 (Scheme 2). These steps were readily
Scheme 4. Synthesis of 2-Substituted Pyrimidine Compounds from Tables 4 and 5, Starting from Common Intermediate 18a
aReagents and conditions: (a) dimethylamine HCl, cesium carbonate, NMP, 180 °C, 1 h; (b) cyclic amine, DIPEA, NMP, 140−180 °C, 1−2 h; (c)
pyrazole, cesium carbonate, NMP, 170 °C, 1 h; (d) 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole, sodium carbonate,
PdCl2(PPh3)2, 1,4-dioxane/water, 130 °C, 30 min; (e) 1-methyl-2-(tributylstannyl)-1H-imidazole, PdCl2(PPh3)2, 1,4-dioxane, 90 °C, 18 h; (f)
bicyclic amine, DIPEA, NMP, 140 °C, 2−8 h.
Scheme 5. Synthesis of 2,4,5-Substituted Pyridine Derivativesa
aReagents and conditions: (a) 16, DIPEA, NMP, 180 °C, 1 h; (b) 3,5-dimethylpyrazole, Xantphos, cesium carbonate. Pd2(dba)3, DMF/toluene,
140 °C, 1 h; (c) DIPEA, THF, 100 °C, 16 h; (d) 16, Xantphos, Pd2(dba)3, cesium carbonate, DMF/toluene, 80 °C, 1 h.
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amenable to scale up, and multigram quantities were produced
without the need for column chromatography.
Aromatic nucleophilic substitution or (for less reactive
pyridine substituents) palladium coupling reactions were used
to prepare the set of compounds shown in Table 3 (Scheme
3).
In order to explore substitution at the pyrimidine-2-position
(Tables 4 and 5), dichloropyrimidine 18 was prepared on
multigram scale. Final compounds were prepared from this,
again via SNAr or metal-catalyzed reactions (Scheme 4).
The reduced reactivity of the pyridine core in comparison to
the pyrimidine meant that metal-catalyzed reactions on bromo-
or iodopyridines or SNAr reactions using 2-fluoropyridines
were used to prepare the pyridyl examples in Table 4 (Scheme
5).
Hit Discovery. A detailed description of our hit discovery
campaign for BCL6 will be presented elsewhere.16 Briefly, we
identified hit compounds 2 and 3 (Table 1) from an in-house
high-throughput screen using a fluorescence polarization (FP)
assay, based on the displacement of a fluorescently labeled
peptide derived from the BCOR co-repressor.7 In common
with other hits from this screen, these compounds showed
weak potency (IC50 ∼100 μM). Initial attempts to obtain
ligand-bound X-ray structures were hindered by solubility
which was lower than their biochemical assay activity (Table
1). To address this, we made analogues with reduced
lipophilicity and fewer aromatic rings. Compounds 4 and 5
demonstrated comparable potency to initial hits and improved
solubility (Table 1), enabling X-ray structure determination.17
Like the BCL6 co-repressors SMRT and BCOR,7 compounds
were found to bind at the dimer interface of the BTB domain
of BCL6 (Figure 1A and Figure 1B). Two interaction features
are common to both 4 and 5: a hydrogen bond from an NH to
the backbone carbonyl of Met51 and the intercalation of their
cyanopyridine moieties into a cleft between Tyr58 and Asn21
on the protein surface, creating a critical hydrophobic
interaction between the cyanopyridine and the side chain of
Tyr58. Compound 4 forms additional interactions via the
oxygen atom of its benzimidazolone core to the backbone N−
H of Glu115 and to the backbone N−H of His116 via a
mediating water molecule. The cyclopropyl group of 5 makes
only weak hydrophobic interactions with the backbone of
residues 53−55 (in blue in Figure 1, also observed for the
benzimidazole of 4), suggesting that the chlorocyanopyridine
of 5 provides much of the binding affinity of this compound.
We therefore hypothesized that combining the benzimidazo-
lone core with the chlorocyanopyridine of 5 would lead to an
increase in potency. Gratifyingly, the resulting compound 6
(CCT365386) showed a significant improvement in binding
affinity, down to ∼10 μM (Table 1).
The X-ray structure of 6 bound to BCL6 confirmed the
hypothesized binding mode, combining the features of 4 and 5
(Figure 1C). Low microsomal clearance and high PAMPA
permeability, combined with good ligand efficiency for a
protein−protein interaction inhibitor hit compound (LE =
0.32 based on the FP assay) further established 6 as a
promising hit compound for optimization. Despite these good
properties, the suboptimal biochemical activity and solubility
meant that we did not observe significant displacement of co-
repressor SMRT from BCL6 in the NanoBRET cellular target
engagement assay (IC50 > 30 μM).
16
Initial Hit Optimization. Having discovered an attractive
starting point, our next objective was to improve the
biochemical potency. To avoid being constrained by the
tight binding limit of the FP assay, we developed new TR-
FRET assay conditions with reduced protein concentration
(from 3 μM used in the FP assay to 1 nM), allowing us to
measure compound activities in the nM range.16 From the X-
ray structure of 6, we identified two main areas for
optimization: first, growing from the benzimidazolone-N3
position into a relatively large cavity, indicated by the arrow
in Figure 1C, and second, by further optimization of the
interactions between the pyridine and the pocket formed by
Tyr58.
Our aim was to gain potency by extending from the N3
position and filling the pocket while ensuring that hydrogen
bond donor or acceptor groups in the binding site were
appropriately satisfied. In our design, we sought to exploit a
Table 1. Potency and Solubility Data for Hit and Early Lead Compounds
aData represent the geometric mean. See Supporting Information Table S1 for full statistics. Potency was later confirmed in the TR-FRET assay
described in the manuscript; see Supporting Information Table S2. bKinetic solubility measured by NMR in HEPES buffer (containing 5% DMSO)
at pH 8. LE calculated as 1.4 × pIC50/HAC.
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hydrophobic patch close to Val18 (Figure 1C) with a n-butyl
chain. This chain would pass close to Asn21, so we
incorporated an alcohol (donor) or nitrile (acceptor) group
to satisfy this interaction, which we hypothesized would also
address the moderate solubility. However, the resulting
compounds 11a and 11b showed no improvement in potency
(Table 2). The X-ray structure of 11a shows both enantiomers
bound to BCL6 with similar occupancies (0.46 and 0.54 for
enantiomers (S) and (R), respectively, Figure 2). We
hypothesized that the weak (3.25 Å) hydrogen bond between
the hydroxyl of the (S) enantiomer of 11a and the side chain of
Asn21 is not sufficient to outweigh the desolvation penalty18,19
and is hence not contributing positively to binding. This was
supported by testing of single enantiomers 11c and 11d and
des-hydroxy 11e, which all have comparable potency.
We sought instead to interact indirectly with BCL6 via the
network of water molecules (Figure 2C) which were observed
in the 11a-bound crystal structure, by changing the position of
the hydroxyl group from the C-2 to C-3 carbon of the butyl
chain. Compound 11f showed a 3-fold improvement in
potency (Table 2), and a crystal structure of 11f bound to
BCL6 (Figure 3A) confirmed the expected binding mode with
interactions to three water molecules. The addition of a methyl
group to form the achiral tertiary alcohol 17a provided a
further improvement in potency, consistent with its increase in
lipophilicity, while maintaining the binding mode to BCL6
(Figure 3B).
17a represented our first submicromolar compound. Further
characterization in the NanoBRET assay demonstrated that
17a is able to disrupt the protein−protein interaction between
full-length co-repressor and BCL6 in cells, albeit with a ∼10-
fold drop-off in activity (NanoBRET IC50 = 8.8 μM, compared
with TR-FRET IC50 = 0.86 μM). To gain further binding
affinity and hence improve cellular potency, we explored
modifications to the pyridine ring (Table 3). The 3-nitrile
group points into a small lipophilic pocket, does not appear to
be making polar interactions, and could be replaced by a
chloro atom (17b). We also assessed whether the potentially
reactive 2-chloropyridine in 17b could be removed and found
that resulting compound 17c maintains activity and improves
solubility.
Figure 1. Structure-guided merging of 5 (A, PDB code 6TOG) and 4 (B, PDB code 6TOF) yielded the more potent 6 (CCT365386) (C, PDB
code 6TOH). The surface of the BCL6 dimer is shown as a grey transparent surface. The two individual monomers are highlighted in gray and
cyan ribbons except for residues 53−55 which are indicated in blue. Key protein residues are shown in line representation. The compounds are
shown as orange ball and sticks, a selected water molecule is shown as a red sphere, and H-bonds are shown as yellow dashed lines. In panel C the
orange arrow indicates an exit vector towards a large accessible pocket close to our compounds. Additional images containing overlays of 4 and 5
with 6 are shown in the Supporting Information Figure S1.
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The crystal structure of BCL6 bound to 17a shows the
pyridine ring making hydrophobic contacts with the electron
rich π-system of Tyr58, and the pyridine nitrogen engaging in a
water-mediated H-bond with Arg28 (Figure 3B). We
hypothesized that a pyrimidine ring could maintain both
these features, and indeed 17d and 17e showed comparable
activity to their pyridine equivalents.
Further functionalization of the pyrimidine or pyridine ring
was explored in order to gain potency. The pyridine 2-position
offers only limited scope for further substitution; the 2-chloro
group in 17a (Figure 3) is largely filling the available space in
this region. Substitution in the pyridine 5-position could give
rise to a steric clash with the phenyl ring of the
benzimidazolone, preventing the molecule from adopting the
binding conformation observed crystallographically: for exam-
ple, addition of a chlorine at this position in 17f leads to a 37-
fold drop in activity compared to parent 17c. The remaining
position (the 2-position on the pyrimidine) was hence selected
for further exploration. Initial examples 17g, 18, and 19
showed that substitution was tolerated, and a set of 2-
heterocyclyl- and heteroarylpyrimidines was therefore prepared
to probe this region (Table 4). A variety of groups including
aliphatic amines and both carbon- or nitrogen-linked
heteroaryl groups were well tolerated in this position,
consistent with the space available in this solvent-exposed
region of the binding site, with hydrophilic groups such as
morpholine 20a showing 4-fold better potency than the more
hydrophobic piperidine 20b.
We attempted to increase potency further by increasing
steric bulk to more completely fill this area of the pocket and
derive additional hydrophobic surface contacts. Addition of
one or two methyl groups to pyrazole (compare 23a, 23b, 23c,
and 23d), piperidine (compare 20b, 24a, and 24b) and
morpholine (compare 20a and 25a) subseries did indeed lead
to an increase in potency, as measured in the TR-FRET assay.
For the most potent examples, pyridine matched-pairs were
prepared but were less potent than their pyrimidine counter-
parts (compare 23d and 26a, or 24b and 26b, or 25a and 26c,
Table 4), in contrast to the matched-pairs for simpler
analogues (compare 17a and 17d, and 17b and 17e; shown
in Table 3). This may be due to the different conformational
preferences of the added substituent: the additional steric clash
resulting from the pyridyl CH compared to the pyrimidine N is
likely to lead to a more twisted minimum energy conformation.
Compounds with submicromolar activity in TR-FRET were
profiled in the cellular NanoBRET assay and showed inhibition
in the low micromolar range. Further substitution on the
morpholine moiety led to 25b, which was our first compound
to show both sub-100 nM activity in the TR-FRET assay and
submicromolar activity in the cellular NanoBRET assay.
X-ray structures obtained for 23d and 25b provided possible
explanations for the observed increases in potency. The
pyrazole group of 23d forms new interactions: a possible
cation−π stacking interaction with Arg24, and a hydrogen
bond from one of the pyrazole nitrogen atoms to Arg28, which
adopts an alternative conformation (Figure 4C and Figure
4D). In contrast, no new polar interactions were observed for
25b (Figure 4A and Figure 4B), which adopts the same
binding mode as parent 17a. We hypothesize that the observed
potency enhancement results from the improved hydrophobic
contacts with Tyr58 and the displacement of water molecules
in this region (Figure 4A and Figure 4B).
Discovery of BCL6 Degraders. In contrast to the
morpholine analogues 25a and 25b, we were surprised to see
no cellular activity for dimethylpiperidine 24b (CCT368682)
in the NanoBRET assay, despite submicromolar potency in the
TR-FRET assay, and good passive permeability (PAMPA Papp
is high [36 × 10−6 cm/s]). A large drop-off from TR-FRET to
NanoBRET potencies was also observed for monomethyl-
piperidine 24a. Upon detailed examination of the NanoBRET
data for 24b, we observed a dose-dependent reduction in total
luminescence, suggesting either cellular toxicity or depletion of
one of the assay components, for example, BCL6 degradation,
as has been previously reported for another series of
inhibitors.15 To investigate this further, we treated SU-DHL-
4 and OCI-Ly1 cells with 24b; Western analysis of cell lysates
demonstrated a concentration-dependent reduction in BCL6
protein levels, consistent with compound-mediated BCL6
degradation (Figure 5). We note also an apparent elevation in
concentration of BCL6 at compound concentrations below the
binding IC50 which is discussed further below.
Degradation of BCL6 represents an attractive alternative to
inhibition. As the protein is removed rather than just inhibited,
activity at substoichiometric concentrations of compound is
possible as the small molecule degrader may act catalytically.
This removes the need for complete continuous occupancy of
BCL6, as the loss of function would be maintained until the
target is regenerated.20 We decided to focus on optimization of
this novel BCL6 degrader, aiming to identify compounds with
suitable physicochemical and pharmacokinetic properties to
Table 2. Structure-Activity Relationships of the
Benzimidazolone-N3 Position (Labeled as R3 Group)
aData represent the geometric mean of at least three replicates. See
Supporting Information Table S2 for full statistics. bKinetic solubility
measured by NMR in HEPES buffer (containing 5% DMSO) at pH 8.
Where this was <30 μM, solubility by HPLC in PBS buffer and 1%
DMSO at pH 7.4 was also measured and is shown in parentheses.
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investigate in vivo degradation of BCL6 in a tumor xenograft
model.
To support optimization, we developed an immunofluor-
escence assay to quantify BCL6 degradation in SU-DHL-4
cells. DC50 values from this assay are shown in Table 4. Initial
SAR appeared tight, with relatively small changes in chemical
structure resulting in the abolition of degradation activity
(Table 4): only the monomethyl- and dimethylpiperidines 24a,
24b, and 26b were identified as degraders, with DC50 values
similar to or below their IC50 values in the TR-FRET assay. No
degradation was observed for pyrazole and morpholine
analogues.
Figure 2. Binding mode of enantiomers of 11a (PDB code 6TOO). Panel A and panel B show the binding mode of the respective (S)- and (R)-
enantiomers of 11a. Panel C shows the (S)-enantiomer and highlights the four water molecules targeted to gain potency. In all panels the surface of
the BCL6 dimer is shown as a gray transparent surface, with the two individual monomers highlighted as ribbons and colored in gray and cyan,
respectively. Selected residues are shown in line representation. Enantiomers of 11a are shown as orange ball and sticks, selected water molecules as
a red spheres, and H-bonds as yellow dashed lines.
Figure 3. Binding mode of 11f and 17a. Panel A and Panel B show the respective BCL6 binding modes of 11f (PDB code 6TOI) and 17a (PDB
code 6TOJ). Compounds are shown as orange ball and sticks, selected water molecules as red spheres, and H-bonds as yellow dashed lines. The
surface of BCL6 dimer is shown as a gray transparent surface. The two individual monomers are displayed as ribbons and colored in gray and cyan,
respectively. Key residues are shown as lines.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.9b02076
J. Med. Chem. 2020, 63, 4047−4068
4053
Optimization of DMPK Properties. Piperidine degraders
24a and 24b were subject to rapid metabolism in mouse
microsomes, which we expected would limit our ability to
achieve sufficient exposure to demonstrate degradation in vivo.
We noted that morpholine 25a (Table 5) had lower
microsomal clearance, leading us to hypothesize that
metabolism of 24a and 24b may be occurring on the more
lipophilic piperidine group. We aimed to reduce microsomal
clearance and hence improve the likelihood of sufficient
exposure21 first by replacing hydrogen atoms with fluorine to
block the potential metabolic sites and second by lowering
lipophilicity.
Trifluorination of the piperidine 3-methyl group showed
modest improvement in microsomal stability (27a), and a
more substantial reduction in clearance was achieved by the
introduction of a difluoro group in the 4-position of the
piperidine. The addition of these fluorine atoms also provided
an improvement in both degradation (DC50) and biochemical
inhibition (IC50), for monomethyl (Table 5, compare 24a and
27c) and dimethyl (compare 24b and 1) piperidine analogues.
In the previously reported series of BCL6 degraders, only
hydrophobic groups were shown to cause degradation.15 We
therefore designed analogues with lower lipophilicity to
investigate whether degradation could be retained with more
hydrophilic groups in this region and as an alternative
approach to lowering metabolic clearance. We chose to modify
the 3-position of the piperidine, as we had already shown that
compounds with hydrophilic groups in the 4-position
(morpholine 25a and piperazine 25c) were not capable of
inducing BCL6 degradation. Hydroxymethyl 27d induced
incomplete degradation, with the response plateauing at ∼60%.
Addition of the 4,4-difluoro moiety was found again to
improve both metabolic stability and the ability of the
molecule to trigger BCL6 degradation, with 27e
(CCT369900) giving potent and full (>85%) degradation
while maintaining excellent aqueous solubility. With 27e we
had thus identified an alternative and, importantly, less
lipophilic group that induced degradation.
Further modifications demonstrated that the structural
requirements for induction of degradation are quite specific:
methylation of the OH reduced degradation (27f); alternative
hydrophilic groups such as nitrile 27g in this position did not
enable degradation; other discrete changes in structure such as
moving the trifluoromethyl group (27h) and constraining the
ring by forming bicyclic groups (28a, 28b) also led to a loss of
degradation activity.
To confirm that degradation was not cell line specific, we
developed an MSD (Meso Scale Discovery) assay to measure
BCL6 levels. Compound 1 (CCT369260), along with
analogues 27b and 27e, shows full (>85%) degradation of
BCL6 in OCI-Ly1 and Karpas 422 cells, at DC50 values
comparable to those observed in the SU-DHL-4 immuno-
fluorescence assay (Table 6). With degradation activity
confirmed, we investigated whether this translated into
antiproliferative activity; examination of degrader compounds
in a 14-day proliferation assay revealed growth inhibition in
both SU-DHL-4 and OCI-Ly1 cell lines. Inhibitor 25b was less
effective, suggesting that depletion of BCL6 gives a stronger
effect on proliferation than inhibition alone, consistent with
previous findings.15 Degraders showed a 5- to 40-fold
reduction in activity in the BCL6 low-expressing22 OCI-Ly3
cell line compared to OCI-Ly1 (Table 6). Degrader 1 was
further profiled in a panel of BCL6-negative cell lines and
showed no antiproliferative activty (Supporting Information
Figure S2). These findings suggest that the observed
antiproliferative activity is driven by on-target effects.
In Vivo Profiling of 1 (CCT369260). On the basis of its
acceptable microsomal clearance and robust effects in
degradation and proliferation assays, compound 1 was selected
for further profiling. A pharmacokinetic study was carried out
in female Balb/C mice, dosing at 1 mg/kg iv (n = 3) and 5
mg/kg po (n = 3). All mice appeared normal after dosing and
24 h after dose. Compound 1 demonstrated moderate
clearance (CL 20 mL min−1 kg−1) with mean oral
bioavailability of 54%. Protein binding measurements using
equilibrium dialysis showed the compound is highly bound
(0.07% free in SCID mouse plasma, n = 6). To enable
comparison of free concentrations in vivo with free levels in the
OCI-Ly1 DC50 MSD assay, the free fraction in the DC50 assay
medium was also measured (2.2% fraction unbound in IMDM
medium, n = 3). This was used to estimate that a free
Table 3. Structure−Activity Relationships of the R4-Group-
Substituted Pyridine and Pyrimidines
aData represent the geometric mean of at least three replicates. See
Supporting Information Table S2 for full statistics. bKinetic solubility
measured by NMR in HEPES buffer (containing 5% DMSO) at pH 8.
Where this was <30 μM, solubility by HPLC in PBS buffer and 1%
DMSO at pH 7.4 was measured and is shown in parentheses.
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Table 4. Structure−Activity Relationships of the Pyrimidine and Pyridine 2-Position (Labeled as R3 Group)
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concentration of greater than 1.1 nM (based on the OCI-Ly1
DC50) is required to elicit degradation in vivo, corresponding
to a total plasma concentration of 1.5 μM or a total blood
concentration of 2.8 μM (SCID mouse blood to plasma ratio
of 1.9). PK studies were carried out at three doses (5, 15, and
50 mg/kg po, Figure 6) to determine if sufficient compound
exposure could be achieved in the SCID mouse strain that
would be used for xenograft studies. Exposure increased with
dose between 5 and 15 mg/kg; however, no improvement was
obtained by a further increase to 50 mg/kg. This is likely due
to compound solubility; the compound was dosed as a clear
solution in saline containing 10% DMSO and 5% Tween 20 at
the lower doses but was not completely soluble and hence was
dosed as a suspension in the same vehicle at the 50 mg/kg
Table 4. continued
aData represent the geometric mean of at least three replicates. See Supporting Information Table S2 for full statistics. bData represent the
geometric mean of at least two replicates except where superscript 1 is indicated. n.d. = not done. cKinetic solubility measured by NMR in HEPES
buffer and 5% DMSO at pH 8, and/or where data are shown in brackets, by HPLC in PBS buffer and 1% DMSO at pH 7.4. #These compounds
showed <10% degradation of BCL6 in single concentration experiments at 10 μM, n = 2.
Figure 4. Binding mode of 25b and 23d. Panels A and B show two different views of the binding mode of 25b (PDB code 6TON). Panels C and D
show two views of the binding mode of 23d (PDB code 6TOK). The panels show the changed conformation of Arg28 and the new interaction with
one of the compound’s pyrazole nitrogen atoms. In all panels, the surface of the BCL6 BTB dimer is shown as a gray transparent surface, with the
two individual monomers displayed as ribbons and colored in gray and cyan. Key residues are shown as lines. Compounds are shown as orange ball
and sticks, selected water molecules as red spheres, and H-bonds as yellow dashed lines.
Figure 5. Treatment of DLBCL cell lines with 24b (CCT368682) leads to degradation of BCL6. SU-DHL-4 or OCI-Ly1 cells were treated with
24b at the indicated concentration for 4 h at 37 °C. Cells were collected, lysed, and examined by Western blot for BCL6 and GAPDH protein
levels. D: DMSO control.
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Table 5. Modifications to the Pyrimidine 2-Substituent
aData represent the geometric mean of at least three replicates. See Supporting Information Table S2 for full statistics. bKinetic solubility measured
by NMR in HEPES buffer and 5% DMSO at pH 8, and/or where data are shown in brackets, by HPLC in PBS buffer and 1% DMSO at pH 7.4.
#These compounds showed <25% degradation of BCL6 in single concentration experiments at 10 μM. n.d. = not done.
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dose. The mean total blood concentration at the 15 mg/kg
dose was above the desired concentration for approximately 10
h, confirming that this compound was suitable for progression
to a PK/PD study at this dose to determine if, and at what
concentration, BCL6 depletion could be achieved.
A PK/PD study was carried out in mice using a single dose
of 1 at 15 mg/kg po in an OCI-Ly1 DLBCL xenograft model.
A clear decrease in levels of BCL6 in the tumor was observed
up to 10 h after dosing with compound 1 (Figure 7 and
Supporting Information Figure S3), with a maximal effect at
∼4 h. No visible adverse events were observed in this study.
Examination of the relationship between compound 1 and
BCL6 levels (Figure 7 and Supporting Information Figure S4)
shows that, consistent with predictions, free concentrations of
>1 nM degrader 1 lead to degradation of BCL6. Less
substantial degradation is observed at 0.5 h; this delayed
onset may be due to the time required for the compound to
distribute into tumor. After compound levels drop below the
calculated free DC50 at the 10 h time point, BCL6 levels
remain low but rebound by 12 and 16 h, presumably due to the
time required for BCL6 resynthesis. This study demonstrates
that degradation of BCL6 in tumors following oral dosing with
a small molecule is a feasible approach.
Table 6. Antiproliferative Activity of Key Compounds
aData represent the geometric mean of at least three replicates. See Supporting Information Table S2 for full statistics. bData represent the
geometric mean of at least two replicates except where superscript i is indicated. #This compound showed <10% degradation of BCL6 in a single
concentration experiment at 10 μM, n = 2.
Figure 6. (Left) Total SCID mouse blood concentrations of 1 (CCT369260) after po dosing at 5 (blue triangles), 15 (red circles), and 50 (green
squares) mg/kg vs predicted active concentration (dashed line). (Right) Data for individual animals showing cmax, tmax, and total AUC10h in SCID
mouse at 5, 15, and 50 mg/kg doses. All experiments were carried out according to the U.K. guidelines for animal experimentation.
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■ DISCUSSION AND CONCLUSIONS
We describe the discovery of a series of benzimidazolone
inhibitors of BCL6, including 1 (CCT369260), an orally
bioavailable degrader of BCL6. Weakly active (100 μM) hits
derived from high throughput screening were merged to give
benzimidazolone lead compound 6 (CCT365386). By filling a
hydrophobic pocket and forming hydrogen bonds to water
molecules, we were able to both improve binding affinity and
incorporate hydrophilic groups to improve solubility. Further
potency improvements were achieved through additional
hydrophobic surface contacts in a solvent-exposed region of
the pocket, resulting in sub-100 nM inhibitors. A subset of
these compounds, including 24b (CCT368682), were shown
to cause rapid degradation of BCL6, initially by Western blot
and by an immunofluorescence assay in SU-DHL-4, and later
confirmed in different cell lines using a MSD assay.
We noted that our initial Western blot data for 24b showed
an apparent increase in BCL6 levels at low concentrations. A
similar effect is also visible in previously presented work on
BCL6 degraders,15 but analysis of curves from MSD
experiments shows that this effect is not observed in all
experiments and, when observed, corresponds to a < 25%
increase. It is noteworthy that we and others15 also observe an
increase in BCL6 levels when cells are treated with
nondegrading inhibitors of BCL6. This suggests that binding
may trigger a feedback mechanism leading to increased
expression of BCL6.
Further optimization of initially identified degrader 24b
enabled us to identify compounds with reduced metabolic
clearance including 27e (CCT369900) and 1 (CCT369260).
CCT369260 showed sub-100 nM activity in a degradation
assay in SU-DHL-4 cells, and robust antiproliferative activity,
in common with previously identified degraders15 but in
contrast to BCL6-targetting PROTACs.14
Similar to previously reported degraders,15 we found that
degradation mediated by our compounds is proteasome-
dependent. It is noteworthy that we observe no significant
difference in binding mode (as observed by X-ray crystallog-
raphy) between 1 (CCT369260) and closely related non-
degrader 25a (Figure 8), suggesting that the inhibitor or
degrader behavior of a compound may depend on the nature
of the substituents in this region of the molecule rather than on
a distinct binding mode.
One possible hypothesis for how degradation is induced is
via formation of a ternary complex of the degrader, BCL6, and
an E3 ligase. In this context, we note that the degrader
compounds including CCT369260 are largely buried in the
BTB domain, with a relatively small area remaining solvent-
exposed and available to bind to another component (for
example, an E3 ligase) and that in contrast to bivalent
PROTAC-type degraders, no hook effect is observed with
increased concentration.23−25 These data suggest that the
degrader molecule alone does not bind potently to an E3 ligase
in the absence of BCL6. One related potential mechanism by
which a small molecule could promote proteosomal degrada-
tion is through “hydrophobic tagging”; the degrader binds to
Figure 7. PK/PD study with 1 (CCT369260) at 15 mg/kg po.
Tumour xenografts were prepared by subcutaneous injection of 1 ×
107 OCI-Ly1 cells in female SCID mice, with dosing of compound
commencing 20 days after injection, to mice with xenografts between
0.5 and 0.8 cm3, as described in more detail in the Supporting
Information. Sampling took place at 0.5, 2, 4, 6, 10, 12, 16 and 24 h
postdose. All experiments were carried out according to the U.K.
guidelines for animal experimentation. BCL6 levels in tumor were
quantified using capillary electrophoresis and normalized to a
GAPDH loading control and are shown as gray (vehicle-treated) or
black (compound treated) bars. Free compound levels at 0.5−24 h
are shown (blue dots); dotted line indicates free DC50.
Figure 8. Binding modes of the BCL6 degrader 1 (CCT369260) (A) and inhibitor 25a (B). Crystal structures of the BCL6 BTB domain bound to
the BCL6 degrader 1 (CCT369260) (A, PDB code 6TOM) and inhibitor 25a (B, PDB code 6TOL) show a nearly identical binding mode. In both
panels, the surface of the BCL6 dimer is shown as a gray transparent surface, with the two individual monomers displayed in ribbons and colored in
gray and cyan. Selected residues are shown as lines. Compounds are shown as orange ball and sticks, selected water molecules as red spheres, and
H-bonds as yellow dashed lines.
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the target protein and presents as a hydrophobic patch on the
protein surface, mimicking a partially unfolded protein state,
which is then targeted for proteosomal degradation.23,24,26
Should this be the case for our BCL6 degraders, then the
incorporation of hydrophilic groups in the solvent-exposed
region would not be expected to be tolerated, and a broad
range of lipophilic groups could be expected to trigger
degradation. However, we show first that certain hydrophilic
groups are tolerated with degradation retained and second that
the structural requirements for degradation are quite specific.
These data together support an alternative hypothesis: that the
combination of the protein surface and the bound degrader
surface generates a “neo-substrate” or “neo-degron” that can be
recognized by an E3 ubiquitin ligase or other effector of
proteasomal degradation. This is similar conceptually to the
mechanism of action of IMiDs which bind strongly to an E3
ligase and generate a “neo-enzyme” surface which modifies the
substrate specificity of the ligase, although in our case it is the
substrate surface, rather than that of the E3 ligase, that we
hypothesize to be modified.
CCT369260 was progressed into PK studies, and we showed
that the levels of compound needed to mediate degradation
could be achieved in vivo following oral dosing, enabling us to
demonstrate depletion of BCL6 levels in tumors following oral
dosing in a mouse xenograft model. Ongoing work includes
further optimization of CCT369260 and the use of our BCL6
degraders as in vitro and in vivo chemical tools to
pharmacologically validate BCL6 as a target for the treatment
of hematological cancer.
■ EXPERIMENTAL SECTION
All in vivo experiments were carried out according to the U.K.
guidelines for animal experimentation. Cell lines were supplied by the
German Collection of Microorganisms and Cell Cultures (DSMZ).
Cell lines were authenticated by STR profiling and were routinely
screened for Mycoplasma, using an in-house PCR-based assay.
General Synthetic Information. All anhydrous solvents and
reagents were obtained from commercial suppliers and used without
further purification. Evaporation of solvent was carried out using a
rotary evaporator under reduced pressure at a bath temperature of up
to 60 °C. Flash column chromatography was carried out using a
Biotage purification system using SNAP KP-Sil cartridges or on
reverse-phase mode using SNAP Ultra C18 cartridges. Semi-
preparative separations were carried out using an Agilent 1200 series
preparative HPLC instrument over a 15 min gradient elution.
Microwave-assisted reactions were carried out using a Biotage
Initiator microwave system. Final compounds were purified to
≥95% purity. NMR data were collected on a Bruker Avance 500
spectrometer equipped with a 5 mm BBO/QNP probe or on a Bruker
Avance Neo 600 spectrometer equipped with a 5 mm TCI
CryoProbe. NMR data are presented in the form of chemical shift
δ (multiplicity, coupling constants, integration) for major diagnostic
protons, given in parts per million (ppm) relative to tetramethylsilane
(TMS), referenced to the internal deuterated solvent. HRMS was
assessed using an Agilent 1200 series HPLC instrument and diode
array detector coupled to a 6120 time-of-flight mass spectrometer
with dual multimode APCI/ESI source or on a Waters Acquity
UHPLC and diode array detector coupled to a Waters G2 QToF
mass spectrometer fitted with a multimode ESI/APCI source.
Preparation of Compounds. 5-((5-Chloro-2-((3R,5S)-4,4-
difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-
(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo-
[d]imidazol-2-one (1, CCT369260). To a mixture of 5-((2,5-
dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-meth-
yl-1,3-dihydro-2H-benzo[d]imidazol-2-one (18) (2.0 g, 5.0 mmol)
were added (3R,5S)-4,4-difluoro-3,5-dimethylpiperidine hydrochlor-
ide (1.03 g, 5.6 mmol), NMP (20.2 mL), and DIPEA (2.64 mL, 15.1
mmol). The resulting mixture was heated to 140 °C for 2 h, cooled to
room temperature, and then poured into ice−water. The resulting
precipitate was collected and washed thoroughly with water to remove
residual NMP, then further washed with ethanol to give a brown solid.
Ethanol filtrate was concentrated and washed with water, then ethanol
to give a second crop of solid. The two solid crops were combined
and suspended in water. Ethanol was added until the brown color was
removed from the solid, which was collected by filtration, washed
again with water, and dried under vacuum to give compound 1 (1.97
g, 3.87 mmol, 77%) as an off-white solid. HRMS (ESI +ve): found
509.2269, expected 509.2243 for C24H32ClF2N6O2 [M + H]
+. δH (600
MHz, CDCl3) 7.98 (s, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.22 (dd, J =
8.3, 2.0 Hz, 1H), 6.99 (s, 1H), 6.94 (d, J = 8.3 Hz, 1H), 4.60 (br d, J =
12.7 Hz, 2H), 4.04 (t, J = 7.4 Hz, 2H), 3.43 (s, 3H), 2.73 (t, J = 12.7
Hz, 2H), 2.32 (s, 1H), 2.02−1.90 (m, 2H), 1.89 (t, J = 7.4 Hz, 2H),
1.29 (s, 6H), 1.05 (d, J = 6.7 Hz, 6H).
2-Chloro-4-((cyclopropylmethyl)amino)nicotinonitrile (5). A
suspension of cyclopropylmethanamine (17 μL, 0.2 mmol), triethyl-
amine (25 μL, 0.18 mmol), and 2,4-dichloronicotinonitrile (30 mg,
0.17 mmol) in DMA (0.35 mL) was stirred at rt for 18 h. The
reaction was quenched with brine and extracted with EtOAc. The
combined organics were washed with water and brine, dried, and
concentrated, then purified by flash column chromatography (0−15%
EtOAc in cyclohexane) to give 5 (26 mg, 0.13 mmol, 72%). δH (500
MHz, CDCl3) 8.09 (d, J = 6.1 Hz, 1H), 6.48 (d, J = 6.1 Hz, 1H), 5.31
(br s, 1H), 3.16−3.10 (m, 2H), 1.19−1.07 (m, 1H), 0.74−0.64 (m,
2H), 0.36−0.30 (m, 2H).
2-Chloro-4-((1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]-
imidazol-5-yl)amino)nicotinonitrile (6, CCT365386). A mixture
of 5-amino-1,3-dimethyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (30
mg, 0.17 mmol), 2,4-dichloronicotinonitrile (30 mg, 0.17 mmol), and
DIPEA (0.032 mL, 0.18 mmol) in DMA (0.4 mL) was heated in the
microwave to 120 °C for 30 min, then added to a 1:1 mixture of
methanol:water. The resulting precipitate was collected, washed
sequentially with water, methanol, diethyl ether and dried to give 6
(32.3 mg, 0.10 mmol, 61%) as a brown solid. HRMS (ESI +ve):
found 314.0810, expected 314.0803 for C15H13ClN5O
+ [M + H]+. δH
(500 MHz, DMSO-d6) 9.50 (s, 1H), 8.01 (d, J = 6.2 Hz, 1H), 7.21 (d,
J = 8.3 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H), 7.00 (dd, J = 8.2, 2.0 Hz,
1H), 6.67 (d, J = 6.2 Hz, 1H), 3.36 (s, 3H), 3.32 (s, 3H).
1-Methyl-5-nitro-1,3-dihydro-2H-benzo[d]imidazol-2-one
(7). To a mixture of N1-methyl-4-nitrobenzene-1,2-diamine (10.5 g,
62.8 mmol) in acetonitrile (150 mL) cooled to 0 °C was added
portionwise disuccinimidyl carbonate (21.7 g, 84.7 mmol) over 20
min. The mixture was stirred at rt for 18 h and then poured into ice−
water, forming a precipitate. The solid was collected by suction
filtration and washed sequentially with water, DCM, and diethyl ether
to give 7 (11.12 g) as an orange-red solid. HRMS (ESI +ve): found
194.0572, expected 194.0560 for C8H8N3O3
+ [M + H]+. δH (500
MHz, DMSO-d6) 11.43 (s, 1H), 8.03 (dd, J = 8.7, 2.3 Hz, 1H), 7.76
(d, J = 2.3 Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H), 3.36 (s, 3H).
2-Chloro-4-((1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]-
imidazol-5-yl)amino)nicotinonitrile (9). To a mixture of 5-amino-
1-methyl-1H-benzo[d]imidazol-2(3H)-one (750 mg, 4.6 mmol) and
2,4-dichloropyridine-3-carbonitrile (760 mg, 4.4 mmol) under argon
was added DMA (10 mL) followed by DIPEA (0.90 mL, 5.19 mmol).
The reaction mixture was heated at 120 °C under microwave
irradiation for 45 min then allowed to cool to rt and added dropwise
to a stirring mixture of methanol:water (1:1; 120 mL). The resulting
precipitate was filtered, washed with water (2 × 25 mL) and diethyl
ether (2 × 30 mL), affording 2-chloro-4-[(1-methyl-2-oxo-3H-
benzimidazol-5-yl)amino]pyridine-3-carbonitrile (1.30 g, 99%, 4.3
mmol) as a beige solid. δH (500 MHz, DMSO-d6) 10.95 (br s, 1H),
9.39 (br s, 1H), 7.99 (d, J = 6.2 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H),
6.95 (dd, J = 8.3, 1.9 Hz, 1H), 6.90 (d, J = 1.9 Hz, 1H), 6.65 (d, J =
6.2 Hz, 1H), 3.29 (s, 3H).
3-(2-Hydroxybutyl)-1-methyl-5-nitro-1,3-dihydro-2H-
benzo[d]imidazol-2-one (10). To a mixture of 1-methyl-5-nitro-
1H-benzo[d]imidazol-2(3H)-one (240 mg, 1.242 mmol) and cesium
carbonate (485 mg, 1.489 mmol) in DMF (3 mL) was added 2-
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ethyloxirane (0.119 mL, 1.367 mmol), and the resulting mixture was
heated in the microwave to 120 °C for 1 h, then added to water (10
mL). The resulting mixture was extracted with DCM, and combined
organics were dried over sodium sulfate, filtered, and evaporated onto
silica gel for purification by flash column chromatography (10 g silica,
40−60% ethyl acetate in cyclohexane). Fractions were combined and
evaporated to give the title compound (200 mg, 60%) as a yellow-
orange oil which solidified on standing. δH (500 MHz, DMSO-d6)
8.13 (d, J = 2.2 Hz, 1H), 8.05 (dd, J = 8.7, 2.3 Hz, 1H), 7.36 (d, J =
8.8 Hz, 1H), 4.90 (d, J = 5.4 Hz, 1H), 3.88 (dd, J = 14.2, 4.2 Hz, 1H),
3.82 (dd, J = 14.2, 7.4 Hz, 1H), 3.70 (m, 1H), 3.41 (s, 3H), 1.49 (m,
1H), 1.37 (m, 1H), 0.92 (t, J = 7.4 Hz, 3H).
2-Chloro-4-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-dihy-
dro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile (11a). To
a suspension of 3-(2-hydroxybutyl)-1-methyl-5-nitro-1,3-dihydro-2H-
benzo[d]imidazol-2-one (10) (34 mg, 0.13 mmol) in ethanol (1.5
mL) and DMSO (0.5 mL) was added sodium dithionite (116 mg,
0.67 mmol). The resulting mixture was heated to 90 °C for 5 h, then
stirred at room temperature for 2 days, then heated again to 90 °C for
2 h. Additional sodium dithionite (116 mg, 0.67 mmol) was added,
and the mixture was heated to 90 °C for 2 h. Water (1 mL) was
added, and the resulting cloudy suspension was stirred at rt for 3 days,
then diluted with water until all was in solution. The pH was adjusted
to 10 using 2 M sodium carbonate, and the resulting mixture was
extracted with DCM (×3), dried by passing through a phase
separator, and evaporated under reduced pressure. The resulting
material was diluted with DMA (0.5 mL), and then 2,4-
dichloronicotinonitrile (15 mg, 0.087 mmol) and DIPEA (25 μL,
0.143 mmol) were added. The resulting mixture was heated in the
microwave to 120 °C for 30 min, then partitioned between DCM and
water. The aqueous layer was acidified to pH 7 using 10% citric acid,
then extracted with DCM (×3). Combined organics were evaporated
and purified by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm column,
15 min gradient from 60:40 to 0:100 water:methanol, 0.1% formic
acid modifier) at a flow rate of 20 mL/min. The resulting yellow oil
was triturated with diethyl ether to give compound 11a (4.2 mg, 0.011
mmol, 8.5%) as pale yellow solid. HRMS (ESI +ve): found 372.1230,
expected 372.1222 for C18H19ClN5O2
+ [M + H]+. δH (500 MHz,
CD3OD) 7.94 (d, J = 6.2 Hz, 1H), 7.22 (d, J = 8.2 Hz, 1H)
overlapping with 7.22 (d, J = 1.9 Hz, 1H), 7.07 (dd, J = 8.4, 1.9 Hz,
1H), 6.70 (d, J = 6.3 Hz, 1H), 3.98−3.89 (m, 1H), 3.89−3.80 (m,
2H), 3.47 (s, 3H), 1.67−1.55 (m, 1H), 1.48 (dp, J = 14.6, 7.3 Hz,
1H), 1.03 (t, J = 7.4 Hz, 3H).
2-Chloro-4-((3-(2-cyanobutyl)-1-methyl-2-oxo-2,3-dihydro-
1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile (11b). To a
mixture of cesium carbonate (70 mg, 0.21 mmol) and 2-chloro-4-
((1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)-
nicotinonitrile (9) (25 mg, 0.08 mmol) in DMF (0.50 mL) was added
2-(bromomethyl)butanenitrile (25 mg, 0.15 mmol). The resulting
mixture was heated to 60 °C for 3 days, then partitioned between
water and DCM, and the aqueous layer acidified to pH 5 using a 10%
citric acid solution. Layers were separated, the aqueous phase was
extracted with further DCM, and combined organics were evaporated
under reduced pressure and then purified by HPLC (ACE 5 C18-PFP
250 mm × 21.2 mm column, 15 min gradient from 45:55 to 30:70
water:methanol, 0.1% formic acid modifier) at a flow rate of 20 mL/
min to give compound 11b as an off-white solid. HRMS (ESI +ve):
found 381.1209, expected 381.1225 for C19H18ClN6O
+ [M + H]+. δH
(500 MHz, CDCl3) 8.04 (d, J = 6.1 Hz, 1H), 7.08 (d, J = 1.9 Hz, 1H),
7.07 (d, J = 8.2 Hz, 1H), 7.02 (dd, J = 8.2, 1.9 Hz, 1H), 6.96 (s, 1H),
6.71 (d, J = 6.1 Hz, 1H), 4.11 (dd, J = 14.4, 5.7 Hz, 1H), 4.04 (dd, J =
14.5, 8.8 Hz, 1H), 3.48 (s, 3H), 3.11 (tt, J = 9.1, 5.4 Hz, 1H), 1.89−
1.69 (m, 2H), 1.19 (t, J = 7.4 Hz, 3H).
(S)-2-Chloro-4-((3-(2-hydroxybutyl)-1-methyl-2-oxo-2,3-di-
hydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile (11c).
To a mixture of 2-chloro-4-((1-methyl-2-oxo-2,3-dihydro-1H-benzo-
[d]imidazol-5-yl)amino)nicotinonitrile (9) (20 mg, 0.067 mmol) and
cesium carbonate (23 mg, 0.07 mmol) in DMF (0.50 mL) was added
(2S)-2-ethyloxirane (7 μL, 0.08 mmol), and the resulting mixture was
heated in the microwave to 120 °C for 1 h. Two further batches of
(2S)-2-ethyloxirane (7 μL, 0.08 mmol) were added, with microwave
heating to 140 °C for 30 min after each. The mixture was partitioned
between water and DCM, and the aqueous layer was acidified to pH 5
using a 10% citric acid solution. Layers were separated, the aqueous
phase was extracted with further DCM, and combined organics were
evaporated under reduced pressure and then purified by HPLC (ACE
5 C18-PFP 250 mm × 21.2 mm column, 15 min gradient from 50:50
to 35:65 water:methanol, 0.1% formic acid modifier) at a flow rate of
20 mL/min to give compound 11c (7.5 mg, 0.020 mmol, 30%) as an
off white solid. HRMS (ESI +ve): found 372.1218, expected 372.1222
for C18H19ClN5O2




Prepared by the same method as its enantiomer 11c, starting from
(2R)-2-ethyloxirane. HRMS (ESI +ve): found 372.1218, expected
372.1222 for C18H19ClN5O2
+ [M + H]+. δH (500 MHz, CD3OD)
identical to racemate 11a.
4-((3-Butyl-1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]-
imidazol-5-yl)amino)-2-chloronicotinonitrile (11e). To 2-
chloro-4-((1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-
amino)nicotinonitrile (9) (25 mg, 0.084 mmol) and cesium carbonate
(33 mg, 0.10 mmol) in DMF (0.85 mL) was added 1-bromobutane
(9.5 μL, 0.089 mmol), and the resulting mixture was stirred at 140 °C
under microwave irradiation for 1 h. Water (10 mL) was added, and
the aqueous mixture was acidified with 1 M HCl. The aqueous
mixture was extracted with EtOAc (5 × 10 mL). The organic extracts
were combined, dried (Na2SO4), and concentrated in vacuo, then
purified by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm column; 15
min gradient of 40:60 to 20:80 water:methanol, 0.1% formic acid
modifier) at a flow rate of 20 mL/min to give compound 11e (12.3
mg, 41%, 0.035 mmol) as an off-white solid. HRMS (ESI +ve): found
356.1263, expected 356.1273 for C18H19ClN5O
+ [M + H]+. δH (500
MHz, CDCl3) 8.03 (d, J = 6.0 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 6.98
(dd, J = 8.1, 1.7 Hz, 1H), 6.93 (br s, 1H), 6.87 (d, J = 1.7 Hz, 1H),
6.60 (d, J = 6.0 Hz, 1H), 3.88 (t, J = 7.3 Hz, 2H), 3.46 (s, 3H), 1.77−




yl)amino)nicotinonitrile (9) (40 mg, 0.13 mmol) and cesium
carbonate (60 mg, 0.18 mmol) in DMF (0.6 mL) was added
[(3R)-3-hydroxybutyl] 4-methylbenzenesulfonate (14b) (55 mg, 0.23
mmol), and the resulting mixture was heated in the microwave to 120
°C for 1 h. The mixture was partitioned between water and DCM,
and the aqueous layer was acidified to pH 5 using a 10% citric acid
solution. Layers were separated, the aqueous phase was extracted with
further DCM, and combined organics were evaporated under reduced
pressure and then purified by HPLC (ACE 5 C18-PFP 250 mm ×
21.2 mm column, 15 min gradient from 50:50 to 35:65 water:-
methanol, 0.1% formic acid modifier) at a flow rate of 20 mL/min to
give compound 11f (21.5 mg, 0.057 mmol, 42%). HRMS (ESI +ve):
found 372.1228, expected 372.1222 for C18H19ClN5O2
+ [M + H]+. δH
(500 MHz, CDCl3) 8.05 (d, J = 6.2 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H),
7.03 (dd, J = 2.0, 8.2 Hz, 1H), 6.97 (d, J = 2.0 Hz, 1H), 6.94 (s, 1H),
6.63 (d, J = 6.2 Hz, 1H), 4.25 (ddd, J = 15.0, 11.0, 4.6 Hz, 1H), 3.88
(dt, J = 15.0, 5.5, 3.8 Hz, 1H), 3.72 (dqd, J = 10.2, 6.2, 2.8 Hz, 1H),
3.49 (s, 3H), 1.88 (dddd, J = 14.1, 11, 5.5, 2.8 Hz, 1H), 1.71 (dddd, J
= 14.1, 10.2, 4.6, 3.8 Hz, 1H), 1.22 (d, J = 6.2 Hz, 3H).
(S)-2-Chloro-4-((3-(3-hydroxybutyl)-1-methyl-2-oxo-2,3-di-
hydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile (11g).
Prepared by the same method as its enantiomer 11f. HRMS (ESI
+ve): found 372.1219, expected 372.1222 for C18H19ClN5O2
+ [M +
H]+. δH (500 MHz, DMSO-d6) 9.48 (s, 1H), 8.00 (d, J = 6.0 Hz, 1H),
7.20 (d, J = 8.2 Hz, 1H), 7.17 (d, J = 1.9 Hz, 1H), 7.00 (dd, J = 1.9,
8.2 Hz, 1H), 6.68 (d, J = 6.0 Hz, 1H), 4.58 (d, J = 4.7 Hz, 1H), 3.94−
3.79 (m, 2H), 3.65−3.58 (m, 1H), 3.34 (s, 3H), 1.72−1.58 (m, 2H),
1.08 (d, J = 6.3 Hz, 3H).
3-Hydroxy-3-methylbutyl 4-methylbenzenesulfonate (14a).
To a solution of 3-methylbutane-1,3-diol (27 g, 0.26 mol) and
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triethylamine (40 mL, 0.29 mol) in DCM (250 mL) at 0 °C was
added dropwise 4-methylbenzenesulfonyl chloride (50 g, 84 mmol) in
200 mL of DCM over 1 h. The resulting mixture was stirred at 0 °C
for 4 h, then water was added (200 mL) and stirred for 45 min.
Adjustment to pH 10 was made by addition of 2 M NaOH and
separated. Organic phase was washed sequentially with 200 mL of
half-saturated sodium bicarbonate solution (×2), water, 1 M HCl,
brine, then dried over magnesium sulfate, filtered, and concentrated to
give a yellow oil. This was dissolved in DCM/cyclohexane and
purified by flash column chromatography (0−40% ethyl acetate in
cyclohexane) to give the title compound (39.9 g) as a colorless oil. δH
(500 MHz, CDCl3) 7.85−7.78 (m, 2H), 7.40−7.34 (m, 2H), 4.23 (t,
J = 6.8 Hz, 2H), 2.47 (s, 3H), 1.88 (t, J = 6.8 Hz, 2H), 1.23 (s, 6H).
[(3R)-3-Hydroxybutyl] 4-methylbenzenesulfonate (14b). A
solution of (3R)-butane-1,3-diol (0.86 mL, 9.5 mmol) in dry
dichloromethane (10 mL) under a nitrogen atmosphere was cooled
in a salt−ice bath (bath temp −12 °C). Triethylamine (2.25 mL, 16.1
mmol) was added followed by a solution of 4-methylbenzenesulfonyl
chloride (2 g, 10.5 mmol) in dry dichloromethane (6 mL) over 10
min. The resulting mixture was allowed to warm slowly to room
temperature and stirred for 20 h, then diluted with DCM, washed
with 10% citric acid, sat. sodium bicarbonate solution, brine, dried
over sodium sulfate, filtered, and evaporated under reduced pressure
to give a clear oil. This was purified by flash column chromatography
(50 g silica, 10−30% ethyl acetate in cyclohexane) to give 14b (1.65
g, 6.75 mmol, 71%) as a clear oil. δH (500 MHz, CDCl3) 7.82 (br d, J
= 8.3 Hz, 2H), 7.37 (br d, J = 7.9 Hz, 2H), 4.26 (ddd, J = 10.0, 8.7,
5.0 Hz, 1H), 4.13 (dt, J = 10.0, 5.5 Hz, 1H), 3.96 (dqd, J = 9.7, 6.2,
3.5 Hz, 1H), 2.47 (s, 3H), 1.85 (dddd, J = 14.5, 8.7, 5.8, 3.6 Hz, 1H),
1.71 (ddt, J = 14.2, 8.9, 5.0 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H).
3-(3-Hydroxy-3-methylbutyl)-1-methyl-5-nitro-1,3-dihydro-
2H-benzo[d]imidazol-2-one (15). A mixture of 1-methyl-5-nitro-
1,3-dihydro-2H-benzo[d]imidazol-2-one (7, 9.05 g, 46.9 mmol),
cesium carbonate (30.5 g, 93.7 mmol), and 3-hydroxy-3-methylbutyl
4-methylbenzenesulfonate (14a, 16.4 g, 63.5 mmol) in acetonitrile
(234 mL) was heated to reflux for 4 h. The mixture was concentrated
under reduced pressure. The residue was then diluted with water (500
mL) and stirred for 30 min, forming a precipitate, which was filtered
and washed thoroughly with water. The collected solid was dried
under vacuum to give 15 (12 g, 43 mmol, 92%) as a red-brown solid.
δH (500 MHz, CDCl3) 8.13 (dd, J = 8.7, 2.0 Hz, 1H), 7.95 (d, J = 2.0
Hz, 1H), 7.04 (d, J = 8.7 Hz, 1H), 4.13 (m, 2H), 3.50 (s, 3H), 1.93
(m, 2H), 1.34 (s, 6H).
5-Amino-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihy-
dro-2H-benzo[d]imidazol-2-one (16). Palladium on activated
charcoal (10% Pd, 240 mg) was added to a solution of 3-(3-
hydroxy-3-methylbutyl)-1-methyl-5-nitro-1,3-dihydro-2H-benzo[d]-
imidazol-2-one (15) (6.3 g, 22.6 mmol) in ethanol (113 mL), which
was then stirred at 60 °C under an atmosphere of hydrogen for 3 h.
The mixture was filtered through a pad of Celite and washed through
with ethanol. The resulting solution was then concentrated under
reduced pressure to give compound 16 (5.85 g) as a pale pink solid.
δH (500 MHz, CD3OD) 6.90 (d, J = 8.1 Hz, 1H), 6.63 (d, J = 1.9 Hz,
1H), 6.58 (dd, J = 8.1, 1.9 Hz, 1H), 3.95 (m, 2H), 3.36 (s, 3H), 1.84
(m, 2H), 1.29 (s, 6H).
2-Chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-
2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)nicotinonitrile
(17a). A mixture of 2,4-dichloropyridine-3-carbonitrile (11 mg, 0.064
mmol), 5-amino-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (16) (15 mg, 0.06 mmol), and DIPEA
(15 μL, 0.086 mmol) in NMP (0.5 mL) was heated in the microwave
to 120 °C for 30 min and then purified by HPLC (ACE 5 C18-PFP
250 mm × 21.2 mm column, 15 min gradient from 45:55 to 20:80
water:methanol, 0.1% formic acid modifier) at a flow rate of 20 mL/
min to give compound 17a (11.2 mg, 0.027 mmol, 46%) as a white
solid. HRMS (ESI +ve): found 386.1388, expected 386.1378 for
C19H21ClN5O2
+ [M + H]+. δH (500 MHz, DMSO-d6) 9.46 (s, 1H),
8.00 (d, J = 6.1 Hz, 1H), 7.20 (d, J = 8.3 Hz, 1H), 7.11 (d, J = 1.9 Hz,
1H), 7.00 (dd, J = 8.3, 2.0 Hz, 1H), 6.68 (d, J = 6.2 Hz, 1H), 4.44 (s,




(17b). A mixture of 5-amino-3-(3-hydroxy-3-methylbutyl)-1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (16) (20 mg, 0.08 mmol),
Xantphos (12 mg, 0.02 mmol), 2,3-dichloro-4-iodopyridine (30 mg,
0.11 mmol), Pd2(dba)3 (2.3 mg, 0.004 mmol), and cesium carbonate
(67 mg, 0.21 mmol) in NMP:toluene (1:1 v/v, 1.8 mL) was degassed
and heated in the microwave under a nitrogen atmosphere at 140 °C
for 1 h. Purification was by reverse-phase flash chromatography
(Biotage Ultra C18 12g, 30−90% methanol in water (0.1% formic
acid modifier)) to give 17b (7 mg, 0.018 mmol, 22%). HRMS (ESI
+ve): found 395.1038, expected 395.1036 for C18H21Cl2N4O2
+ [M +
H]+. δH (600 MHz, CDCl3) 7.90 (d, J = 5.6 Hz, 1H), 7.03 (d, J = 8.2
Hz, 1H), 7.01 (dd, J = 8.2, 1.8 Hz, 1H), 6.95 (d, J = 1.8 Hz, 1H), 6.68
(s, 1H), 6.64 (d, J = 5.7 Hz, 1H), 4.09−4.03 (m, 2H), 3.46 (s, 3H),
1.93−1.87 (m, 2H), 1.32 (s, 6H).
5-((3-Chloropyridin-4-yl)amino)-3-(3-hydroxy-3-methylbu-
tyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (17c).
Method as for 17b, using 4-bromo-3-chloropyridine. Purified by
HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm column, 15 min
gradient from 40:60 to 25:75 water:methanol, 0.1% formic acid
modifier) at a flow rate of 20 mL/min to give compound 17c (21 mg,
69%, 0.055 mmol) as the formic acid salt. HRMS (ESI +ve): found
361.1422, expected 361.1426 for C18H22ClN4O2
+ [M + H]+. δH (500
MHz, acetone-d6) 8.30 (s, 1H), 8.16 (s, 1H), 8.06 (d, J = 5.7 Hz, 1H),
7.18−7.13 (m, 2H), 7.06 (dd, J = 8.1, 2.0 Hz, 1H), 6.84 (d, J = 5.7
Hz, 1H), 4.03 (t, J = 8.2 Hz, 2H), 3.41 (s, 3H), 1.85 (t, J = 8.2 Hz,
2H), 1.25 (s, 6H).
4-Chloro-6-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-oxo-
2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)pyrimidine-5-
carbonitrile (17d). Method as for 17a, using 4,6-dichloropyrimi-
dine-5-carbonitrile and heating at 80 °C for 30 min. 17d (8.2 mg, 0.02
mmol, 33%) obtained as an off white solid. HRMS (ESI +ve): found
387.1340, expected 387.1331 for C18H20ClN6O2
+ [M + H]+ . δH (500
MHz, DMSO-d6) 10.25 (br s, 1H), 8.49 (s, 1H), 7.23 (s, 1H), 7.14 (s,
2H), 4.45 (br s, 1H), 3.93−3.81 (m, 2H), 3.33 (s, 3H), 1.75−1.64
(m, 2H), 1.16 (s, 6H).
5-((5,6-Dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-
methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-
one (17e). A mixture of 5-amino-3-(3-hydroxy-3-methylbutyl)-1-
methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (16) (30 mg, 0.12
mmol), DIPEA (30 uL, 0.17 mmol), and 4,5,6-trichloropyrimidine
(26 mg, 0.14 mmol) in DMF (0.9 mL) was heated in the microwave
to 120 °C for 30 min. The mixture was partitioned between water and
DCM, and the aqueous layer was acidified to pH 4 using a 10% citric
acid solution. Layers were separated, the aqueous phase was extracted
with further DCM, and combined organics were evaporated under
reduced pressure and then purified by reverse phase flash
chromatography (Biotage 12g SNAP Ultra C18, 20−100% methanol
in water, 0.1% formic acid modifier) and then further triturated with
diethyl ether to give compound 17e as a beige solid (41 mg, 0.10
mmol, 86%). HRMS (ESI +ve): found 396.0997, expected 396.0989
for C17H20Cl2N5O2
+ [M + H]+. δH (500 MHz, DMSO-d6) 9.46 (s,
1H), 8.26 (s, 1H), 7.30 (d, J = 2.0 Hz, 1H), 7.21 (dd, J = 8.4, 2.0 Hz,
1H), 7.13 (d, J = 8.4 Hz, 1H), 4.45 (s, 1H), 3.91−3.84 (m, 2H), 3.33
(s, 3H, obscured by solvent), 1.74−1.66 (m, 2H), 1.16 (s, 6H).
5-((3,5-Dichloropyridin-4-yl)amino)-3-(3-hydroxy-3-methyl-
butyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one
(17f). Method as for 17b, using 4-bromo-3,5-dichloropyridine.
Obtained compound 17f (8 mg, 0.02 mmol, 25%). HRMS (ESI
+ve): found 395.1027, expected 395.1036 for C18H21Cl2N4O2
+ [M +
H]+. δH (600 MHz, CDCl3) 8.34 (s, 2H), 6.92 (d, J = 8.2 Hz, 1H),
6.78 (dd, J = 8.2, 2 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 6.58 (s, 1H),




imidazol-2-one (17g). Method as for 17e, using 4,5-dichloro-2-
methylsulfanylpyrimidine. Obtained compound 17g as white solid (27
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mg, 0.063 mmol, 78%). HRMS (ESI +ve): found 408.1208, expected
408.1255 for C18H23ClN5O2S
+ [M + H]+ ]+. δH (500 MHz, DMSO-
d6) 8.43 (br s, 1H), 8.24 (s, 1H), 7.41 (d, J = 1.6 Hz, 1H), 7.27 (dd, J
= 8.4, 1.6 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 3.87 (m, 2H), 3.32 (s,
3H), 2.38 (s, 3H), 1.72 (m, 2H), 1.17 (s, 6H).
5-((2,5-Dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-
methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-
one (18). A mixture of 5-amino-3-(3-hydroxy-3-methylbutyl)-1-
methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (16) (1.61 g, 6.47
mmol), 2,4,5-trichloropyrimidine (0.88 mL, 7.69 mmol), and cesium
carbonate (4.21 g, 12.93 mmol) in DMF (15 mL) was heated in the
microwave to 120 °C for 30 min. The resulting mixture was diluted
with water, acidified to pH 5 by addition of 10% citric acid, and
extracted with DCM. The combined organics were evaporated under
reduced pressure, and the resulting sticky solid was dissolved in a
minimum volume of ethyl acetate and precipitated by addition of
diethyl ether. The resulting solid was collected by filtration and
washed with diethyl ether and dried under reduced pressure, giving
the title product (1.96 g, 72%, 4.69 mmol) as a solid. δH (500 MHz,
DMSO-d6) 9.57 (s, 1H), 8.34 (s, 1H), 7.35 (d, J = 1.9 Hz, 1H), 7.19
(dd, J = 8.4, 1.9 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 4.44 (s, 1H),
3.92−3.86 (m, 2H), 3.33 (s, 3H), 1.76−1.69 (m, 2H), 1.17 (s, 6H).
5-((5-Chloro-2-(dimethylamino)pyrimidin-4-yl)amino)-3-(3-
hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]-
imidazol-2-one (19). A mixture of 5-((2,5-dichloropyrimidin-4-
yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-
benzo[d]imidazol-2-one (18) (20 mg, 0.05 mmol), dimethylamine
hydrochloride (37 mg, 0.45 mmol), cesium carbonate (164 mg, 0.50
mmol) in NMP (0.5 mL) was heated in the microwave to 180 °C for
1 h. Mixture was partitioned between DCM and water, aqueous layer
was extracted with DCM, and combined organics were washed with
Brine. Organic layers were combined and evaporated, and the
resulting NMP solution was purified by HPLC (ACE 5 C18-PFP 250
mm × 21.2 mm column; 15 min gradient of 40:60 to 25:75
water:methanol, 0.1% formic acid modifier) at a flow rate of 20 mL/
min to give compound 19 (8 mg, 0.0188 mmol, 37%). HRMS (ESI
+ve): found 405.1790, expected 405.1800 for C19H26ClN6O2
+. δH
(500 MHz, acetone-d6) 7.96 (s, 1H), overlapping with 7.98−7.94
(0.6H, partly exchanged NH), 7.73 (d, J = 1.7 Hz, 1H), 7.35 (dd, J =
8.1, 1.7 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 4.02 (t, J = 7.9 Hz, 2H),
3.38 (s, 3H), 3.13 (s, 6H), 1.85 (t, J = 7.9 Hz, 2H), 1.25 (s, 6H).
5-((5-Chloro-2-morpholinopyrimidin-4-yl)amino)-3-(3-hy-
droxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]-
imidazol-2-one (20a). A mixture of morpholine (0.031 mL, 0.25
mmol), 5-((2,5-dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-meth-
ylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (18, 20
mg, 0.05 mmol), and DIPEA (0.04 mL, 0.25 mmol) in NMP (1
mL) was heated in the microwave to 180 °C for 1 h, then partitioned
between DCM and water. The aqueous layer was extracted with
DCM, and combined organics were washed with brine. The organic
layers were combined and evaporated, and the resulting material
(containing residual NMP) was purified by preparative HPLC (ACE
5 C18-PFP column (5 μm, 250 mm × 21.2 mm), 15 min gradient
elution from 40:60 to 25:75 water:methanol (both modified with
0.1% formic acid) at a flow rate of 20 mL/min) to give 20a (18 mg,
0.038 mmol, 76%). HRMS (ESI +ve): found 447.1897, expected
447.1906 for C21H28ClN6O3
+ [M + H]+. δH (500 MHz, CD3OD)
7.92 (s, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.31 (dd, J = 8.4, 1.7 Hz, 1H),
7.10 (d, J = 8.4 Hz, 1H), 4.00 (m, 2H), 3.70−3.67 (m, 4H), 3.66−
3.62 (m, 4H), 3.41 (s, 3H), 1.84 (m, 2H), 1.28 (s, 6H).
5-((5-Chloro-2-(piperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-
hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]-
imidazol-2-one (20b). Method as for 20a, using piperidine and
heating to 170 °C for 1 h. Obtained compound 20b (19 mg, 0.04
mmol, 80%) following HPLC. HRMS (ESI +ve): found 445.2111,
expected 445.2113 for C22H30ClN6O2
+ [M + H]+. δH (500 MHz,
acetone-d6) 7.97 (br, partly exchanged NH, 0.3H), 7.96 (s, 1H), 7.61
(d, J = 1.8 Hz, 1H), 7.31 (dd, J = 8.7, 1.3 Hz, 1H), 7.05 (d, J = 8.7 Hz,
1H), 4.02 (m, 2H), 3.73 (br t, J 4.8 Hz, 4H), 3.38 (s, 3H), 1.86 (m,
2H), 1.67−1.62 (m, 2H), 1.59−1.52 (m, 4H), 1.25 (s, 6H).
5-((5-Chloro-2-(2,4-dimethylthiazol-5-yl)pyrimidin-4-yl)-
amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (21). A mixture of 5-((2,5-dichlor-
opyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-
dihydro-2H-benzo[d]imidazol-2-one (18) (20 mg, 0.05 mmol), 2,4-
dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole
(12.07 mg, 0.05 mmol), sodium carbonate (10.7 mg, 0.10 mmol), and
bis(triphenylphosphine)palladium(II) chloride (1.8 mg, 0.0025
mmol) in 1,4-dioxane (0.40 mL) and water (0.40 mL) was heated
in the microwave at 130 °C for 30 min. The mixture was partitioned
between DCM and water and pH adjusted to 5 using 10% citric acid
before separation and extraction with further DCM. The organic
layers were combined and evaporated, and the resulting solution was
purified by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm column, 15
min gradient from 40:60 to 25:75 water:methanol, 0.1% formic acid
modifier) at a flow rate of 20 mL/min to give compound 21 (2 mg,
0.0042 mmol, 8%) as a white solid. HRMS (ESI +ve): found
473.1501, expected 473.1521 for C22H26ClN6O2S
+ [M + H]+. δH (500
MHz, acetone-d6) 8.50 (br, 1H), 8.38 (s, 1H), 7.54 (d, J = 1.8 Hz,
1H), 7.34 (dd, J = 8.3, 1.8 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 4.07 (t, J
= 7.9 Hz, 2H), 3.41 (s, 3H), 2.63 (s, 3H), 2.60 (s, 3H), 1.89 (t, J = 7.9
Hz, 2H), 1.24 (s, 6H).
5-((5-Chloro-2-(1-methyl-1H-imidazol-2-yl)pyrimidin-4-yl)-
amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (22). A mixture of 1-methyl-2-
(tributylstannyl)-1H-imidazole (21 mg, 0.06 mmol), 5-((2,5-dichlor-
opyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-
dihydro-2H-benzo[d]imidazol-2-one (18) (20 mg, 0.05 mmol), and
bis(triphenylphosphine)palladium(II) chloride (3.5 mg, 0.005 mmol)
in 1,4-dioxane (1 mL) was heated for 18 h at 90 °C. The mixture was
partitioned between DCM and water and pH adjusted to 5 using 10%
citric acid before separation and extraction with further DCM. The
organic layers were combined and evaporated, and the resulting
solution was purified by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm
column, 15 min gradient from 40:60 to 25:75 water:methanol, 0.1%
formic acid modifier) at a flow rate of 20 mL/min to give compound
22 (3 mg, 0.0068 mmol, 13%) as the formic acid salt. HRMS (ESI
+ve): found 442.1740, expected 442.1753 for C21H25ClN7O2
+ [M +
H]+. δH (500 MHz,, acetone-d6) 8.50 (br, 1H), 8.37 (s, 1H), 8.12 (s,
1H), 7.74 (br s, 1H), 7.64 (br s, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.35
(dd, J = 8.6, 2.0 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 4.04 (t, J = 8.3 Hz,
2H), 3.91 (s, 3H), 3.40 (s, 3H), 1.88 (t, J = 8.3 Hz, 2H), 1.24 (s, 6H).
5-((5-Chloro-2-(1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-
hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]-
imidazol-2-one (23a).Method as for 19, using 1H-pyrazole, heating
in the microwave to 170 °C for 1 h. Purified by HPLC (ACE 5 C18-
PFP 250 mm × 21.2 mm column; 15 min gradient of 60:40 to 0:100
water:methanol, 0.1% formic acid modifier) at a flow rate of 20 mL/
min to give compound 23a. HRMS (ESI +ve): found 428.1552,
expected 428.1596 for C20H23ClN7O2
+ [M + H]+. δH (500 MHz,
DMSO-d6) 9.42 (br, 1H), 8.45 (s, 1H), 8.38 (d, J = 2.2 Hz, 1H), 7.79
(s, 1H), 7.63 (d, J = 2.2 Hz, 1H), 7.42 (dd, J = 8.4, 2.2 Hz, 1H), 7.17
(d, J = 8.4 Hz, 1H), 6.52 (s, 1H), 3.91 (t, J = 7.6 Hz, 2H), 3.34 (s,
3H), 1.75 (t, J = 7.6 Hz, 2H), 1.14 (s, 6H).
5-((5-Chloro-2-(3-methyl-1H-pyrazol-1-yl)pyrimidin-4-yl)-
amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (23b) and 5-((5-Chloro-2-(5-meth-
yl-1H-pyrazol-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-
methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-
one (23c). A mixture of 5-((2,5-dichloropyrimidin-4-yl)amino)-3-(3-
hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-
2-one (18) (25 mg, 0.063 mmol), 3-methylpyrazole (0.05 mL, 0.62
mmol), and cesium carbonate (100 mg, 0.31 mmol) in NMP (0.5
mL) was heated in the microwave to 170 °C for 1 h. The mixture was
partitioned between DCM and water and pH adjusted to 5 using 10%
citric acid before separation and extraction with further DCM. The
organic layers were combined and evaporated, and the resulting
solution was purified by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm
column; 15 min gradient of 45:55 to 20:80 water:methanol, 0.1%
formic acid modifier) at a flow rate of 20 mL/min. Two products
were obtained: the major, later eluting regioisomer was assigned as
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compound 23b (18 mg, 0.039 mmol, 61%). HRMS (ESI +ve): found
442.1755, expected 442.1753 for C21H25ClN7O2
+ [M + H]+. δH (500
MHz, CDCl3) 8.34 (s, 1H), 8.27 (d, J = 2.6 Hz, 1H), 7.63 (d, J = 2.0
Hz, 1H), 7.32 (s, 1H, NH), 7.18 (dd, J = 8.3, 2.0 Hz, 1H), 7.02 (d, J =
8.3 Hz, 1H), 6.23 (d, J = 2.6 Hz, 1H), 4.15−4.08 (m, 2H), 3.47 (s,
3H), 2.40 (s, 3H), 1.94 (t, J = 7.3 Hz, 2H), 1.30 (s, 6H). The minor,
earlier eluting regioisomer was assigned as compound 23c (2.5 mg,
0.005 mmol, 8.5%). HRMS (ESI +ve): found 442.1756, expected
442.1753 for C21H25ClN7O2
+ [M + H]+. δH (500 MHz,, CDCl3) 8.37
(s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.63 (m, 1H), 7.29 (s, 1H, NH),
7.08 (dd, J = 8.3, 2.0 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.16 (s, 1H),




2H-benzo[d]imidazol-2-one (23d). Method as for 23b, using 3,5-
dimethyl-1H-pyrazole. Purified by HPLC (ACE 5 C18-PFP 250 mm
× 21.2 mm column; 15 min gradient of 40:60 to 25:75
water:methanol, 0.1% formic acid modifier) at a flow rate of 20
mL/min, then further purified by flash column chromatography (12 g
KP-SIL, 0−6% methanol in DCM) to give compound 23d. HRMS
(ESI +ve): found 456.1928, expected 456.1909 for C22H27ClN7O2 [M
+ H]+. δH (500 MHz, CDCl3) 8.37 (s, 1H), 7.44 (d, J = 1.9 Hz, 1H),
7.22 (s, 1H), 7.13 (dd, J = 1.9, 8.2 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H),
5.95 (s, 1H), 4.08 (t, J = 7.3 Hz, 2H), 3.45 (s, 3H), 2.33 (s, 3H), 2.31
(s, 3H), 1.89 (t, J = 7.4 Hz, 2H), 1.35−1.22 (m, 6H).
5-((5-Chloro-2-(3-methylpiperidin-1-yl)pyrimidin-4-yl)-
amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (24a). Method as for 20a, using 3-
methylpiperidine and heating to 170 °C for 1 h. Obtained 24a (18
mg, 0.037 mmol, 74%) as the formic acid salt after HPLC purification.
HRMS (ESI +ve): found 459.2239, expected 459.2270 for
C23H32ClN6O2
+ [M + H]+. δH (500 MHz, acetone-d6) 8.14 (s, 1H,
formic acid), 7.98 (br, 0.8H, partly exchanged NH), 7.95 (s, 1H), 7.57
(d, J = 2.0 Hz, 1H), 7.35 (dd, J = 8.8, 2.0 Hz, 1H), 7.06 (d, J = 8.8 Hz,
1H), 4.59−4.50 (m, 2H), 4.01 (m, 2H), 3.37 (s, 3H), 2.83 (td, J =
12.5, 2.9 Hz, 1H), 2.51 (dd, J = 12.9, 10.6 Hz, 1H), 1.86 (m, 2H),
1.80 (dm, J = 12.9 Hz, 1H),1.69 (dp, J = 13.2, 3.4 Hz, 1H), 1.57 (m,
1H), 1.46 (qt, J = 13.2, 12.5, 12, 4 Hz, 1H), 1.25 (s, 6H), 1.16 (app
qd, J = 12.1, 3.8 Hz, 1H), 0.90 (d, J = 6.1 Hz, 2H).
5-((5-Chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)-
pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (24b). Method as for
20a using (3R,5S)-3,5-dimethylpiperidine. Obtained 24b (11 mg,
0.022 mmol, 88%) as the formic acid salt. HRMS (ESI +ve): found
473.2392, expected 473.2426 for C24H34ClN6O2
+ [M + H]+. δH (500
MHz, acetone-d6) 8.31 (br s, 0.6H, partly exchanged NH), 8.13 (s,
1H), 7.96 (s, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.39 (dd, J = 8.4, 2.0 Hz,
1H), 7.09 (d, J = 8.4 Hz, 1H), 4.66 (br d, J = 12.6 Hz, 2H), 4.04 (m,
2H), 3.39 (s, 3H), 2.33 (dd, J = 12.6, 11.7 Hz, 2H), 1.86 (m, 2H),




dro-2H-benzo[d]imidazol-2-one (25a). Method as for 20a, using
(2R,6S)-2,6-dimethylmorpholine and heating to 170 °C for 1 h.
Obtained compound 25a (16 mg, 0.032 mmol, 63%) after HPLC
purification. HRMS (ESI +ve): found 475.2169, expected 475.2219
for C23H32ClN6O3 [M + H]
+. δH (500 MHz, acetone-d6) 8.07 (br,
1H), 7.98 (s, 1H), 7.57 (d, J = 1.8 Hz, 1H), 7.31 (dd, J = 8.7, 1.8 Hz,
1H), 7.07 (d, J = 8.7 Hz, 1H), 4.46 (dd, J = 13.3, 2.3 Hz, 2H), 4.03 (t,
J = 8.0 Hz, 2H), 3.55 (dqd, J = 10.5, 6.2, 2.3 Hz, 2H), 3.37 (s, 3H),
2.48 (dd, J = 13.3, 10.5 Hz, 2H), 1.86 (t, J = 8.0 Hz, 2H), 1.26 (s,
6H), 1.16 (d, J = 6.2 Hz, 6H).
5-((5-Chloro-2-(2,2,6,6-tetramethylmorpholino)pyrimidin-
4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihy-
dro-2H-benzo[d]imidazol-2-one (25b). A mixture of 5-((2,5-
dichloropyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-meth-
yl-1,3-dihydro-2H-benzo[d]imidazol-2-one (18) (30 mg, 0.076
mmol), 2,2,6,6-tetramethylmorpholine (22 mg, 0.15 mmol), and
DIPEA (40 μL, 0.23 mmol) in NMP (0.67 mL) was heated in the
microwave to 140 °C for 2 h. Once cooled, the mixture was diluted
with DMSO (0.5 mL) and then purified by reverse-phase
chromatography eluting from 30% to 100% methanol in water
(each containing 0.1% formic acid) to give compound 25b (32 mg,
0.064 mmol, 84%) as a pale brown solid. HRMS (ESI +ve): found
503.2521, expected 503.2532 for C25H36ClN6O3
+ [M + H]+. δH (600
MHz, CDCl3) 7.97 (s, 1H), 7.36 (d, J = 2.0 Hz, 1H), 7.24 (dd, J =
8.4, 2.0 Hz, 1H), 7.00 (s, 1H), 6.93 (d, J = 8.4 Hz, 1H), 4.04 (t, J =
7.2 Hz, 2H), 3.58 (s, 4H), 3.42 (s, 3H), 1.89 (t, J = 7.2 Hz, 2H), 1.28
(s, 6H), 1.23 (s, 12H).
5-((5-Chloro-2-((3S,5R)-3,4,5-trimethylpiperazin-1-yl)-
pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (25c). Method as for
25b, using (2S,6R)-1,2,6-trimethylpiperazine and heating for 1 h at
140 °C. Purification by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm
column; 15 min gradient of 90:10 to 0:100 water:methanol, 0.1%
formic acid modifier) at a flow rate of 20 mL/min followed by further
purification using an SCX-2 column gave compound 25c (2 mg, 0.004
mmol, 11%). HRMS (ESI +ve): found 488.2518, expected 488.2535
for C24H35ClN7O2
+ [M + H]+. δH (600 MHz, CD3OD) 7.94 (s, 1H),
7.43 (d, J = 2.0 Hz, 1H), 7.37 (dd, J = 8.4, 2.0 Hz, 1H), 7.14 (d, J =
8.4 Hz, 1H), 4.40 (br d, J = 13.4 Hz, 2H), 4.04 (m, 2H), 3.45 (s, 3H),
2.70 (dd, J = 13.4, 11.0 Hz, 2H), 2.34 (s, 3H), 2.32−2.22 (m, 2H),
1.87 (m, 2H), 1.30 (s, 6H), 1.15 (d, J = 6.2 Hz, 6H).
5-((5-Chloro-2-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-4-yl)-
amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (26a). A mixture of 3,5-dimethyl-1H-
pyrazole (3 mg, 0.03 mmol), Pd2(dba)3 (1.5 mg, 0.0017 mmol),
Xantphos (4.1 mg, 0.007 mmol), cesium carbonate (14 mg, 0.04
mmol), and 5-((2-bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-
3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one
(29, 9 mg, 0.02 mmol) in NMP:toluene (1:1 v/v, 0.8 mL) was heated
in the microwave to 140 °C for 1 h. The resulting mixture was diluted
with water, acidified to pH 5 by addition of 10% citric acid, then
extracted with DCM (5 mL × 3). Organic layer was collected and
passed through a Si-DMT palladium scavenging column, then
evaporated under reduced pressure. Product was purified by HPLC
(ACE 5 C18-PFP 250 mm × 21.2 mm column; 15 min gradient of
40:60 to 25:75 water:methanol, 0.1% formic acid modifier) at a flow
rate of 20 mL/min to give 26a (4 mg, 0.0084 mmol, 41%). HRMS
(ESI +ve): found 455.1943, expected 455.1957 for C23H28ClN6O2
+
[M + H]+. δH (500 MHz, acetone-d6) 8.19−8.14 (m, 1.6H, including
partly exchanged NH), 7.39 (s, 1H), 7.19−7.16 (m, 2H), 7.09 (dd, J
= 8.2, 2.0 Hz, 1H), 5.97 (s, 1H), 4.03 (t, J = 7.9 Hz, 2H), 3.42 (s,
3H), 2.57 (s, 3H), 2.10 (s, 3H), 1.87 (t, J = 7.9 Hz, 2H), 1.23 (6H, s).
5-((5-Chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)pyridin-
4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihy-
dro-2H-benzo[d]imidazol-2-one (26b). A mixture of 5-amino-3-
(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]-
imidazol-2-one (16, 15 mg, 0.06 mmol), 5-chloro-2-((3S,5R)-3,5-
dimethylpiperidin-1-yl)-4-iodopyridine 30a (25.3 mg, 0.072 mmol),
cesium carbonate (157 mg, 0.48 mmol), Xantphos (20.9 mg, 0.036
mmol), and Pd2(dba)3 (5.5 mg, 0.006 mmol) in toluene:DMF (3:1 v/
v, 0.8 mL) was heated in the microwave at 80 °C for 1 h. EtOAc and
aq NH4Cl were added, layers were separated, and aqueous layer was
extracted with further EtOAc. The organic layers were combined,
dried over MgSO4, and concentrated under vacuum. Purification was
by flash column chromatography (0−10% MeOH in DCM), followed
by further purification by HPLC (ACE 5 C18-PFP 250 mm × 21.2
mm column; 15 min gradient of 60:40 to 0:100 water:methanol, 0.1%
formic acid modifier) at a flow rate of 20 mL/min to give compound
26b (13 mg, 0.028 mmol, 46%) as formic acid salt. HRMS (ESI +ve):
found 472.2482, expected 472.2474 for C25H35ClN5O2
+ [M + H]+. δH
(500 MHz, CD3OD) 8.27 (br, 1H), 7.84 (s, 1H), 7.22 (d, J = 8.3 Hz,
1H), 7.18 (d, J = 1.8 Hz, 1H), 7.10 (dd, J = 8.3, 1.8 Hz, 1H), 6.12 (s,
1H), 4.03 (m, 2H), 3.81 (dm, J = 13 Hz, 2H), 3.46 (s, 3H), 2.30 (dd,
J = 13, 11.4 Hz, 2H), 1.86 (m, 2H), 1.80 (m, 1H), 1.62 (m, 2H), 1.28
(s, 6H), 0.87 (d, J = 6.6 Hz, 6H), 0.76 (dt, J = 12.9, 11.8 Hz, 1H).
5-((5-Chloro-2-((2R,6S)-2,6-dimethylmorpholino)pyridin-4-
yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihydro-
2H-benzo[d]imidazol-2-one (26c). Method as for 26b, using
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(2S,6R)-4-(5-chloro-4-iodo-2-pyridyl)-2,6-dimethylmorpholine 30b.
Further purification by HPLC (ACE 5 C18-PFP 250 mm × 21.2
mm column; 15 min gradient of 45:55 to 20:80 water:methanol, 0.1%
formic acid modifier) at a flow rate of 20 mL/min gave compound
26c (5 mg, 0.011 mmol, 26%). HRMS (ESI +ve): found 474.2246,
expected 474.2266 for C24H33ClN5O3
+ [M + H]+. δH (500 MHz,,
CD3OD) 7.86 (s, 1H), 7.21 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 1.6 Hz,
1H), 7.09 (dd, J = 8.3, 1.6 Hz, 1H), 6.13 (s, 1H), 4.03 (m, 2H), 3.73
(br dd, J = 12.3, 2.3 Hz, 2H), 3.63 (m, 2H), 3.46 (s, 3H), 2.34 (dd, J




dro-2H-benzo[d]imidazol-2-one (27a). Method as for 20a, using
3-(trifluoromethyl)piperidine, with heating for 1 h at 170 °C.
Obtained compound 27a (13 mg, 0.025 mmol, 50%) after purification
by HPLC. HRMS (ESI +ve): found 513.1980, expected 513.1987 for
C23H29ClF3N6O2
+ [M + H]+. δH (500 MHz, acetone-d6) 8.11 (br s,
1H), 8.00 (s, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.37 (dd, J = 8.4, 1.6 Hz,
1H), 7.05 (d, J = 8.4 Hz, 1H), 4.88 (br d, J = 12.5 Hz, 1H), 4.63 (br
d, J = 13.3 Hz, 1H), 4.06−3.98 (m, 2H), 3.38 (s, 3H), 2.96−2.85 (m,




2H-benzo[d]imidazol-2-one (27b). Method as for 25b, using 4,4-
difluoropiperidine, with heating for 1 h at 140 °C. Purification by
HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm column; 15 min
gradient of 90:10 to 0:100 water:methanol, 0.1% formic acid
modifier) at a flow rate of 20 mL/min gave compound 27b (11
mg, 0.023 mmol. 55%). HRMS (ESI +ve): found 503.1729, expected
503.1744 for C22H27ClF2N6NaO2
+ [M + Na]+. δH (600 MHz,
CD3OD) 7.94 (s, 1H), 7.44 (d, J = 1.9 Hz, 1H), 7.32 (dd, J = 8.4, 2.0
Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 4.11−3.95 (m, 2H), 3.84 (br t, J =
5.9 Hz, 4H), 3.43 (s, 3H), 1.95 (tt, J = 13.8, 5.9 Hz, 4H), 1.89−1.79
(m, 2H), 1.29 (s, 6H).
5-((5-Chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-
pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (27c). Method as for
27b, using 4,4-difluoro-3-methylpiperidine. Obtained compound 27c
(11 mg, 0.022 mmol, 52%) as hemiformic acid salt. HRMS (ESI +ve):
found 495.2087, expected 495.2081 for C23H30ClF2N6O2
+ [M + H]+.
δH (600 MHz, CD3OD) 8.28 (s, 0.5H, formic), 7.94 (s, 1H), 7.42 (d,
J = 1.9 Hz, 1H), 7.35 (dd, J = 8.4, 2.0 Hz, 1H), 7.13 (d, J = 8.4 Hz,
1H), 4.40 (br d, J = 13.6 Hz, 1H), 4.32 (br d, J = 13.4 Hz, 1H), 4.09−
3.96 (m, 2H), 3.44 (s, 3H), 3.28 (ddd, J = 13.6, 11.4, 3.4 Hz, 1H)),
2.98 (dd, J = 13.4, 10.2 Hz, 1H), 2.15−1.95 (m, 2H), 1.87 (m, 2H)




dro-2H-benzo[d]imidazol-2-one (27d). Method as for 27b, using
piperidin-3-ylmethanol. Obtained 27d (18.5 mg, 0.039 mmol, 77%)
as formic acid salt. HRMS (ESI +ve): found 475.2224, expected
475.2219 for C23H32ClN6O3
+ [M + H]+. δH (600 MHz, CD3OD)
8.14 (br s, 1H), 7.89 (s, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.39 (dd, J =
8.4, 2.0 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 4.47 (dd, J = 13.1, 3.7 Hz,
1H), 4.32 (dt, J = 13.1, 4.2 Hz, 1H), 4.02 (m, 2H), 3.46 (dd, J = 10.9,
5.7 Hz, 1H), 3.42 (s, 3H), overlapping with 3.41 (dd, J = 10.9, 7.2 Hz,
1H), 3.01 (td, J = 13.1, 11.2, 3.1 Hz, 1H), 2.80 (dd, J = 13.1, 10.1 Hz,
1H), 1.89−1.80 (m, 3H), 1.74−1.66 (m, 2H), 1.49 (m, 1H), 1.34−




as for 27b, using (4,4-difluoro-3-piperidyl)methanol. Obtained 27e
(13 mg, 0.025 mmol, 65%) as formic acid salt. HRMS (ESI +ve):
found 511.2036, expected 511.2030 for C23H30ClF2N6O3
+ [M + H]+.
δH (600 MHz, CD3OD) 8.22 (s, 1H), 7.95 (s, 1H), 7.43 (d, J = 1.9
Hz, 1H), 7.41 (dd, J = 8.4, 1.9 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 4.50
(br d, J = 13.6 Hz, 1H), 4.26 (m, 1H), 4.03 (m, 2H), 3.88 (dd, J =
11.2, 4.1 Hz, 1H), 3.48 (dd, J = 11.2, 9.2 Hz, 1H), 3.44 (m, 1H)
overlapping with 3.43 (s, 3H), 3.31 (dd, J = 13.6, 9.4 Hz, 1H), 2.13
(m, 1H), 2.01 (m, 1H), 1.96−1.86 (m, 1H) overlapping with 1.87 (m,




as for 27b, using 4,4-difluoro-3-(methoxymethyl)piperidine. Obtained
27f (5 mg, 0.001 mmol, 22%) as formic acid salt. HRMS (ESI +ve):
found 525.2171, expected 525.2187 for C24H32ClF2N6O3
+ [M + H]+.
δH (600 MHz, CD3OD) 8.22 (formic acid), 7.96 (s, 1H), 7.47 (d, J =
1.9 Hz, 1H), 7.36 (dd, J = 8.4, 1.9 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H),
4.56−4.46 (br d, J = 13.6 Hz, 1H), 4.39−4.29 (dm, J = 13.6 Hz, 1H),
4.05 (m, 2H), 3.66 (dd, J = 9.6, 3.6 Hz, 1H), 3.45 (s, 3H), 3.41−3.35
(m, 1H), 3.32−3.33 (m, 1H), 3.27−3.22 (m, 1H), 3.22 (s, 3H),
2.28−2.17 (m, 1H), 2.07−1.97 (m, 1H), 1.97−1.90 (m, 1H), 1.87
(dd, J = 9.1, 7.3 Hz, 2H), 1.30 (s, 6H).
1-(5-Chloro-4-((3-(3-hydroxy-3-methylbutyl)-1-methyl-2-
oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)amino)pyrimidin-
2-yl)piperidine-3-carbonitrile (27g). Method as for 27b, using
piperidine-3-carbonitrile hydrochloride. Obtained 27g (20 mg, 0.04
mmol, 80%). HRMS (ESI +ve): found 470.2053, expected 470.2066
for C23H29ClN7O2
+ [M + H]+. δH (600 MHz, CD3OD) 7.93 (d, J =
1.1 Hz, 1H), 7.45 (d, J = 2.0 Hz, 1H), 7.33 (dd, J = 8.4, 2.0 Hz, 1H),
7.11 (dd, J = 8.4, 1.1 Hz, 1H), 4.06−3.99 (m, 2H), 3.93 (d, J = 5.2
Hz, 2H), 3.78−3.66 (m, 2H), 3.42 (s, 3H), 2.95−2.88 (m, 1H),
2.06−1.98 (m, 1H), 1.96−1.84 (m, 2H + 1H), 1.80−1.70 (m, 1H),
1.64−1.54 (m, 1H), 1.29 (s, 6H).
5-((5-Chloro-2-(4-(trifluoromethyl)piperidin-1-yl)pyrimidin-
4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-1,3-dihy-
dro-2H-benzo[d]imidazol-2-one (27h). Method as for 27b, using
4-(trifluoromethyl)piperidine. Obtained 27h (18 mg, 0.035 mmol,
82%) as formic acid salt. HRMS (ESI +ve): found 535.1787, expected
535.1807 for C23H28ClF3N6NaO2
+ [M + Na]+. δH (600 MHz,
CD3OD) 8.21 (s, 1H), 7.92 (s, 1H), 7.46 (d, J = 1.9 Hz, 1H), 7.33
(dd, J = 8.4, 1.9 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 4.68 (dt, J = 13.5,
2.8 Hz, 2H), 4.01 (m, 2H), 3.43 (s, 3H), 2.85 (td, J = 13.5, 12.7, 2.6
Hz, 2H), 2.42 (m (tqt), 1H), 1.95−1.77 (m, 4H), 1.46 (qd, J = 12.6,
4.4 Hz, 2H), 1.29 (s, 6H).
5-((5-Chloro-2-(8,8-difluoro-3-azabicyclo[3.2.1]octan-3-yl)-
pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (28a). Method as for
25b, using 8,8-difluoro-3-azabicyclo[3.2.1]octane hydrochloride.
Purification by HPLC (ACE 5 C18-PFP 250 mm × 21.2 mm
column; 15 min gradient of 90:10 to 0:100 water:methanol, 0.1%
formic acid modifier) at a flow rate of 20 mL/min gave compound
28a (9.5 mg, 0.019 mmol, 45%) as hemiformic acid salt. HRMS (ESI
+ve): found 507.2073, expected 507.2081 for C24H30F2N6O2Cl
+ [M +
H]+. δH (600 MHz, CD3OD) δ 8.19 (s, 0.5H, formic), 7.94 (s, 1H),
7.47 (d, J = 2.0 Hz, 1H), 7.33 (dd, J = 8.4, 2.0 Hz, 1H), 7.12 (d, J =
8.4 Hz, 1H), 4.41 (br d, J = 13.4 Hz, 2H), 4.02 (m, 2H), 3.43 (s, 3H),
3.23 (br d, J = 12.9 Hz, 2H), 2.28 (m, 2H), 1.90−1.83 (m, 4H),
1.65−1.53 (m, 2H), 1.29 (s, 6H).
5-((5-Chloro-2-(3,3-difluoro-8-azabicyclo[3.2.1]octan-8-yl)-
pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1-methyl-
1,3-dihydro-2H-benzo[d]imidazol-2-one (28b). Method as for
27b, using 3,3-difluoro-8-azabicyclo[3.2.1]octane hydrochloride and
heating in the microwave at 140 °C for 8 h. Obtained compound 28b
(12.5 mg, 0.025 mmol, 59%) as a cream solid. HRMS (ESI +ve):
found 507.2087, expected 507.2081 for C24H30ClF2N6O2
+ [M + H]+.
δH (600 MHz, DMF-d7) 8.84 (s, 1H), 8.14 (s, 1H), 7.66 (d, J = 1.9
Hz, 1H), 7.47 (dd, J = 8.4, 2.0 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 4.71
(br s, 2H), 4.52 (s, 1H), 4.04 (m, 2H), 3.42 (s, 3H), 2.33−2.12 (m,
4H), 2.09−1.93 (m, 4H), 1.86 (m, 2H), 1.26 (s, 6H).
5-((2-Bromo-5-chloropyridin-4-yl)amino)-3-(3-hydroxy-3-
methylbutyl)-1-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-
one (29). A mixture of 5-amino-3-(3-hydroxy-3-methylbutyl)-1-
methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (16) (20 mg, 0.08
mmol), 2,4-dibromo-5-chloropyridine (25 mg, 0.092 mmol), and
DIPEA (16 mg, 0.12 mmol) in NMP (0.5 mL) was heated in the
microwave to 180 °C for 1 h, then diluted with water, acidified to pH
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5 by addition of 10% citric acid, then extracted with DCM (5 mL ×
3). Combined organics were evaporated under reduced pressure and
purified by reverse phase column chromatography (12 g C18 column,
30−80% MeOH in water, both modified with 0.1% formic acid) to
give 29 (9 mg, 0.019 mmol, 24%). HRMS (ESI +ve): found 439.0512,
expected 439.0531 for C18H21BrClN4O2
+ [M + H]+. δH (500 MHz,
acetone-d6) 8.08 (s, 1H), 7.92 (br, 0.6H, partly exchanged NH), 7.17
(d, J = 8.4 Hz, 1H), 7.15 (m, 1H), 7.08 (dt, J = 8.4, 1.7 Hz, 1H), 6.83
(d, J = 4.3 Hz, 1H), 4.04 (m, 2H), 3.42 (s, 3H), 1.86 (m, 2H), 1.26
(s, 6H).
5-Chloro-2-((3S,5R)-3,5-dimethylpiperidin-1-yl)-4-iodopyri-
dine (30a). A solution of cis-3,5-dimethylpiperidine (0.23 g, 2.0
mmol), 5-chloro-2-fluoro-4-iodopyridine (0.53 g, 2.0 mmol), and
DIPEA (0.53 mL, 3.1 mmol) in THF (8 mL) was heated in a sealed
vial to 100 °C for 16 h. When cooled, water was added to the THF
solution and extracted with EtOAc. The combined organic layers were
washed with water twice and dried with sodium sulfate. Flash column
chromatography (4% ethyl acetate in cyclohexane) gave 30a (488 mg,
1.39 mmol, 68%) as a white solid. δH (500 MHz, DMSO-d6) 8.08 (s,
1H), 7.40 (s, 1H), 4.36−4.10 (m, 2H), 2.25 (dd, J = 12.9, 11.4 Hz,
2H), 1.75 (dtd, J = 10.6, 3.6, 1.9 Hz, 1H), 1.62−1.46 (m, 2H), 0.88
(d, J = 6.6 Hz, 6H), 0.84−0.70 (m, 1H).
(2S,6R)-4-(5-Chloro-4-iodopyridin-2-yl)-2,6-dimethylmor-
pholine (30b). Prepared as for 30a, using (2S,6R)-2,6-dimethylmor-
pholine, with heating for 3 days. Flash column chromatography (10%
ethyl acetate in cyclohexane) gave 30b (54 mg, 0.15 mmol, 39%) as a
white waxy solid. δH (500 MHz, DMSO-d6) 8.13 (s, 1H), 7.43 (s,
1H), 4.22−4.06 (m, 2H), 3.66−3.50 (m, 2H), 2.39 (dd, J = 12.8, 10.5
Hz, 2H), 1.14 (d, J = 6.1 Hz, 6H).
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APCI, atmospheric pressure chemical ionization; BCL6, B-cell
lymphoma 6 protein; BCOR, BCL-6 co-repressor protein;
BRET, bioluminescence resonance energy transfer; BTB,
broad-complex, tramtrack, and bric a brac (domain), also
known as POZ (poxvirus and zinc finger) domain; CL,
clearance; CLint, intrinsic clearance; cmax, maximum (peak)
concentration achieved after a single dose; cPr, cyclopropyl;
DC50, concentration of compound at which 50% of the
maximally observed protein degradation (Dmax) is achieved;
DIPEA, N,N-diisopropylethylamine; DLBCL, diffuse large B-
cell lymphoma; Dmax, maximal percentage degradation of
protein achieved; EtOAc, ethyl acetate; GAPDH, glyceralde-
hyde 3-phosphate dehydrogenase; HAC, heavy atom count;
IMDM, Iscove’s modified Dulbecco’s medium; IMiD,
immunomodulatory imide drug, such as thalidomide and its
analogues; MeCN, acetonitrile; MLM, mouse liver microsome;
MSD, meso scale discovery, an assay method similar to ELISA,
using electrochemiluminescence as a detection technique;
NanoBRET, a BRET-based assay format commercialized by
Promega that uses NanoLuc luciferase to generate the donor
signal and a HaloTag ligand as the fluorescent energy acceptor;
NCoR, nuclear receptor co-repressor 1; PFP, pentafluor-
ophenyl; PPI, protein−protein interaction; PROTAC, proteol-
ysis targeting chimera; QToF, quadrupole time-of-flight;
SCID, severe combined immunodeficient (mouse model);
SCX-2, SCX (strong cation exchange)-2, which is a
propylsulfonic acid bonded sorbent; Si-DMT, silica bound
equivalent of 2,4,6-trimercaptotriazine; SMRT, silencing
mediator for retinoid or thyroid hormone receptor (also
known as nuclear receptor co-repressor 2 or NCoR2); SNAr,
nucleophilic aromatic substitution; sol., solubility; STR, short
tandem repeat (analysis); tmax, time after dosing at which the
maximum (peak) concentration cmax is observed; TR-FRET,
time-resolved fluorescence energy transfer; Xantphos, 4,5-
bis(diphenylphosphino)-9,9-dimethylxanthene
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